var title_f19_33_19984="Complete fracture radius";
var content_f19_33_19984=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Complete fracture radius",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 525px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nondisplaced slightly angulated complete fracture of distal radius with normal ulna in 9-year-old. Treated with short arm cast without reduction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paula Schweich, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_33_19984=[""].join("\n");
var outline_f19_33_19984=null;
var title_f19_33_19985="Calculator: Harvey-Bradshaw index of Crohn's disease activity";
var content_f19_33_19985=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"HarveyBradshaw_form\" name=\"HarveyBradshaw_form\" onkeydown=\"document.HarveyBradshaw_form.cctotal.value='';\" onkeyup=\"HarveyBradshaw_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Harvey-Bradshaw index of Crohn's disease activity",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Patient sense of general well being in the last 24 hours",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"HarveyBradshaw_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Very well (0 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"HarveyBradshaw_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Somewhat below normal (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"HarveyBradshaw_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Poor (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"HarveyBradshaw_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Very poor (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"HarveyBradshaw_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Terrible (4 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Patient report of abdominal pain in last 24 hours",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc2\" onclick=\"HarveyBradshaw_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         None (0 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc2\" onclick=\"HarveyBradshaw_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Mild (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc2\" onclick=\"HarveyBradshaw_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Moderate (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc2\" onclick=\"HarveyBradshaw_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Severe (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Number of liquid stools in last 24 hours",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc3\" onchange=\"HarveyBradshaw_fx();\" size=\"3\" type=\"text\" value=\"\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Stools",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Finding of an abdominal mass",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc4\" onclick=\"HarveyBradshaw_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         No mass (0 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc4\" onclick=\"HarveyBradshaw_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Possible mass (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc4\" onclick=\"HarveyBradshaw_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Definite mass (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc4\" onclick=\"HarveyBradshaw_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Mass present and tender (4 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Complications",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc5\" onclick=\"HarveyBradshaw_fx();\" type=\"checkbox\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Arthralgias (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc6\" onclick=\"HarveyBradshaw_fx();\" type=\"checkbox\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Uveitis (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc7\" onclick=\"HarveyBradshaw_fx();\" type=\"checkbox\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Erythema nodosum (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc8\" onclick=\"HarveyBradshaw_fx();\" type=\"checkbox\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Aphthous ulcers (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc9\" onclick=\"HarveyBradshaw_fx();\" type=\"checkbox\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Pyoderma gangrenosum (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc10\" onclick=\"HarveyBradshaw_fx();\" type=\"checkbox\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Anal fissure (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc11\" onclick=\"HarveyBradshaw_fx();\" type=\"checkbox\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Newly discovered fistula (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc12\" onclick=\"HarveyBradshaw_fx();\" type=\"checkbox\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Abcess (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontCCTabBold\">",
"     Total Criteria Point Count:",
"    </span>",
"    <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"   </form>",
"   <span class=\"medCalcFontOneBold\">",
"    Notes",
"   </span>",
"   <ul class=\"medCalcFontOne\">",
"    <li>",
"     A Harvey-Bradshaw Index of &lt;5 correlates with clinical remission.",
"    </li>",
"    <li>",
"     Please see appropriate UpToDate topic reviews for further information.",
"    </li>",
"   </ul>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"   <span class=\"medCalcFontRef\">",
"    <b>",
"     References",
"    </b>",
"   </span>",
"   <ol>",
"    <li>",
"     <span class=\"medCalcFontRef\">",
"      Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity.",
"      <i>",
"       Lancet",
"      </i>",
"      . 1980 Mar 8;1(8167):514.",
"     </span>",
"    </li>",
"   </ol>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    /* &lt;![CDATA[ */",
"",
";",
"HarveyBradshaw_fx();",
"/* ]]&gt; */",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_33_19985=[" /* <![CDATA[ */",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function HarveyBradshaw_fx() {",
"with(document.HarveyBradshaw_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1[0].checked){",
"Score = Score + 0;",
"}",
"if (cc1[1].checked){",
"Score = Score + 1;",
"}",
"if (cc1[2].checked){",
"Score = Score + 2;",
"}",
"if (cc1[3].checked){",
"Score = Score + 3;",
"}",
"if (cc1[4].checked){",
"Score = Score + 4;",
"}",
"if (cc2[0].checked){",
"Score = Score + 0;",
"}",
"if (cc2[1].checked){",
"Score = Score + 1;",
"}",
"if (cc2[2].checked){",
"Score = Score + 2;",
"}",
"if (cc2[3].checked){",
"Score = Score + 3;",
"}",
"thisvalue = parseFloat(cc3.value);",
"if (isNaN(thisvalue)) thisvalue = 0;",
"ThisScore =  thisvalue * 1 + 0;",
"Score =  Score + ThisScore;",
"if (cc4[0].checked){",
"Score = Score + 0;",
"}",
"if (cc4[1].checked){",
"Score = Score + 1;",
"}",
"if (cc4[2].checked){",
"Score = Score + 3;",
"}",
"if (cc4[3].checked){",
"Score = Score + 4;",
"}",
"if (cc5.checked){",
"Score = Score + 1;",
"}",
"if (cc6.checked){",
"Score = Score + 1;",
"}",
"if (cc7.checked){",
"Score = Score + 1;",
"}",
"if (cc8.checked){",
"Score = Score + 1;",
"}",
"if (cc9.checked){",
"Score = Score + 1;",
"}",
"if (cc10.checked){",
"Score = Score + 1;",
"}",
"if (cc11.checked){",
"Score = Score + 1;",
"}",
"if (cc12.checked){",
"Score = Score + 1;",
"}",
"cctotal.value = Score;",
"}",
"}",
"",
"",
"",
"",
"",
"",
"/* ]]> */"].join("\n");
var outline_f19_33_19985=null;
var title_f19_33_19986="Lyme vector map";
var content_f19_33_19986=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Lyme disease vector map",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The geographical distribution of the Ixodes tick vectors of the spirochetes that cause Lyme disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn with permission from: Eisen L, Lane RS. Vectors of Borrelia burgdorferi sensu lato. In: Lyme Borreliosis Biology, Epidemiology and Control, Gray JS, Kahl O, Lane RS, et al (Eds), CABI Publishing, Wallingford, Oxon, UK 2002. p. 91. Copyright &copy;2002 CAB International, Wallingford, UK.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_33_19986=[""].join("\n");
var outline_f19_33_19986=null;
var title_f19_33_19987="Duodenal switch";
var content_f19_33_19987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F54159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F54159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Biliopancreatic diversion with duodenal switch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 443px; height: 526px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The biliopancreatic diversion with duodenal switch procedure involves a partial sleeve gastrectomy with preservation of the pylorus, and creation of a Roux limb with a short common channel. This procedure has significant risks of long-term malabsorption and is used only for patients with very severe obesity (BMI &gt;50 kg/m",
"    <sup>",
"     2",
"    </sup>",
"    ).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jones DB, Schneider BE, Olbers T. Atlas of Metabolic and Weight Loss Surgery. Cine-Med, North Woodbury, Connecticut 2010. Copyright &copy; 2010 Cine-Med.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_33_19987=[""].join("\n");
var outline_f19_33_19987=null;
var title_f19_33_19988="Chapter 6A: Mechanisms of hormone action";
var content_f19_33_19988=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 6A: Mechanisms of hormone action",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/33/19988/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/33/19988/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/33/19988/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/33/19988/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/33/19988/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/33/19988/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/33/19988/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/33/19988/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 15, 2000.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding chapters discussed the reabsorptive and secretory functions of the individual nephron segments. These processes are affected by a variety of hormones, some of which are synthesized within the kidney such as renin (see Chap. 2), calcitriol (the most active metabolite of vitamin D), prostaglandins, and kinins. As will be seen, these hormones play an important role in the maintenance of fluid and electrolyte balance, since they allow the",
"    <strong>",
"     individual regulation",
"    </strong>",
"    of the rate of excretion of the different solutes and water. The kidney also secretes erythropoietin, a hormone that promotes red cell production by the bone marrow.",
"   </p>",
"   <p>",
"    This chapter will review the major mechanisms of action and the regulation of secretion of those hormones that have important effects on renal function. How these hormones interact with other factors to permit the maintenance of fluid and electrolyte balance will then be discussed in Chapters 8 to 12.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS OF HORMONE ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hormones that influence renal function generally work by activating specific cellular proteins via phosphorylation or by inducing the synthesis of new proteins. A hormone can initiate these events by affecting adenylyl cyclase, guanylyl cyclase, phosphatidylinositol turnover, or, with steroid hormones, RNA transcription (",
"    <a class=\"graphic graphic_figure graphicRef76815 \" href=\"UTD.htm?9/61/10192\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19988/abstract/1-9\">",
"     1-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Adenylyl cyclase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the responses mediated by adenylyl cyclase begin by attachment of the hormone to its specific receptor on the basolateral membrane of the tubular cell. This hormone-receptor complex then affects the activation state of a guanine nucleotide regulatory protein, such as the stimulatory (Gs) or inhibitory (Gi) proteins (",
"    <a class=\"graphic graphic_figure graphicRef67240 \" href=\"UTD.htm?17/30/17902\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19988/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Gs, for example, has three components, alpha (alpha), beta (beta), and gamma (gamma), with the alpha subunit normally binding guanosine diphosphate (GDP) in the inactive state. Binding of hormone to its receptor causes the alpha subunit to release GDP, take up intracellular guanosine triphosphate (GTP), and at least partially dissociate from the beta-gamma subunit. This Galpha-GTP complex is able to activate adenylyl cyclase, leading to the conversion of ATP into cyclic AMP.",
"   </p>",
"   <p>",
"    The generation of cyclic AMP is followed sequentially by activation of a protein kinase (due to cyclic AMP binding to a regulatory subunit on the kinase [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19988/abstract/10\">",
"     10",
"    </a>",
"    ]), phosphorylation of specific cell proteins (by the transfer of phosphate from intracellular ATP to the protein), and the physiologic effects of the hormone. Hormone activity is eventually shut off by a GTPase intrinsic to the Galpha molecule that hydrolyzes bound GTP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19988/abstract/1\">",
"     1",
"    </a>",
"    ]. The beta-gamma subunit also may be an important regulator of these processes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19988/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, activation of Gi results in diminished adenylyl cyclase activity and a reduction in cellular cyclic AMP levels [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19988/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. As with Gx, Gi also dissociates into alpha, beta, and gamma subunits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Guanylyl cyclase",
"    </span>",
"    &nbsp;&mdash;&nbsp;An analogous but separate intracellular pathway involves the activation of guanylyl cyclase, leading to the subsequent formation of cyclic guanosine monophosphate (GMP) and phosphorylation of specific cell proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19988/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This pathway appears to mediate the actions of atrial natriuretic peptide (see below) and of direct vasodilators, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    and nitroglycerine.",
"   </p>",
"   <p>",
"    The initial event in this system is, for atrial natriuretic peptide, attachment to its extracellular receptor on the cell membrane. This transmembrane protein has a conserved intracellular regulatory and cyclase catalytic domain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19988/abstract/6,12\">",
"     6,12",
"    </a>",
"    ]. Stimulatory and inhibitory regulatory proteins, as with adenylyl cyclase, do not seem to be involved.",
"   </p>",
"   <p>",
"    Binding of ANP to its receptor appears to induce a conformational change (such as dimerization) in the kinase domain, leading to activation of guanylyl cyclase activity and the generation of cyclic GMP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19988/abstract/5\">",
"     5",
"    </a>",
"    ]. In the kidney, this process leads to closing of Na+ channels in the luminal membrane in the inner medullary collecting duct (see below), are not well understood [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19988/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Phosphatidylinositol turnover",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another mechanism of hormone action involves the turnover of membrane lipids. This process is again initiated by binding of the hormone (eg, angiotensin II and norepinephrine) to its cell receptor, leading to the activation of a G protein (called Gq, as compared to Gs that stimulates adenylyl cyclase) and the formation of Galpha-GTP (",
"    <a class=\"graphic graphic_figure graphicRef70144 \" href=\"UTD.htm?19/31/19966\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19988/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. In this setting, however, membrane-bound phospholipase C is activated, rather than adenylyl cyclase.",
"   </p>",
"   <p>",
"    Phospholipase C then promotes the breakdown of a membrane lipid, phosphatidylinositol 4,5-biphosphate into two compounds: inositol 1,4,5-triphosphate (IP3) and diacylglycerol. IP3 mediates the acute effect of the hormone by increasing the release of calcium from stores in endoplasmic reticulum and by enhancing the uptake of extracellular calcium. The net effect is an elevation in the cytosolic calcium concentration. This calcium binds to calmodulin, leading to the phosphorylation of specific cell proteins and the physiologic effects of the hormone.",
"   </p>",
"   <p>",
"    The calcium effect, however, is short-lived and sustained action of the hormone is mediated by diacylglycerol, which activates protein kinase C. The latter compound then causes the desired changes in cell activity.",
"   </p>",
"   <p>",
"    The formation of diacylglycerol may also play an additional role, since the fatty acid at position 2 is arachidonic acid, the precursor of the prostaglandins. Arachidonic acid can be released from diacylglycerol by phospholipase A2, an enzyme that can be hormonally activated. This may explain, for example, how ADH increases local prostaglandin production and, in part, how prostaglandins then modulate the actions of ADH (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19988/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     RNA transcription",
"    </span>",
"    &nbsp;&mdash;&nbsp;Steroid hormones, such as aldosterone, calcitriol, and cortisol, have a different mechanism of action, involving new protein synthesis (",
"    <a class=\"graphic graphic_figure graphicRef56745 \" href=\"UTD.htm?4/61/5086\">",
"     figure 4",
"    </a>",
"    ). These hormones are lipid-soluble and therefore are able to diffuse across the cell membrane and combine with specific receptors that are located in the cytosol rather than the cell membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19988/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Attachment of hormone to its receptor results in unmasking of the DNA-binding site on the receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19988/abstract/8,9,16\">",
"     8,9,16",
"    </a>",
"    ]. As a result, the hormone-receptor complex is able to migrate into the nucleus and to bind to specific sites near the genes that are responsible for the physiologic actions of the hormone. Subsequent steps include messenger RNA and ribosomal RNA transcription and the eventual synthesis of new proteins.",
"   </p>",
"   <p>",
"    The discovery of analogs of steroid hormones, which have different receptor complex binding properties than the endogenous hormones, may permit the administration of agents that possess the desirable properties of these hormones but circumvent their adverse effects. As an example, oxacalcitriol, a vitamin-D or calcitriol analog, has a low affinity for vitamin D-binding protein; as a result, more of the drug circulates in the free (unbound) form, allowing it to be more rapidly metabolized than calcitriol [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19988/abstract/17\">",
"     17",
"    </a>",
"    ]. This leads to a shorter half-life that could explain the small and transient stimulation of intestinal calcium absorption and a lower likelihood of inducing hypercalcemia than with calcitriol itself. The ability to minimize the risk of hypercalcemia with a vitamin D analog may be important clinically when given to suppress secondary hyperparathyroidism in patients with chronic renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A more important clinical example of tissue selective activity occurs with selective estrogen receptor modulators, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    . In vitro experiments suggest that raloxifene has different effects from estradiol at the estrogen receptor, including differential modulation of DNA response elements [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19988/abstract/18\">",
"     18",
"    </a>",
"    ] and causing a different conformational change in the transactivation domain of the ligand-binding domain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19988/abstract/19\">",
"     19",
"    </a>",
"    ]. In patients, raloxifene preserves the beneficial effects of estrogen on bone and apparently the heart [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19988/abstract/20\">",
"     20",
"    </a>",
"    ] without promoting endometrial hyperplasia or increasing the risk of breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19988/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41576?source=see_link\">",
"     \"Managing the side effects of tamoxifen\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=see_link\">",
"     \"Chapter 6B: Antidiuretic hormone and water balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19988/abstract/1\">",
"      Spiegel AM, Weinstein LS, Shenker A. Abnormalities in G protein-coupled signal transduction pathways in human disease. J Clin Invest 1993; 92:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19988/abstract/2\">",
"      Miller RT. Transmembrane signalling through G proteins. Kidney Int 1991; 39:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19988/abstract/3\">",
"      Neer EJ. Heterotrimeric G proteins: organizers of transmembrane signals. Cell 1995; 80:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19988/abstract/4\">",
"      Vaughan M. Signaling by heterotrimeric G proteins minireview series. J Biol Chem 1998; 273:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19988/abstract/5\">",
"      Wong SK, Garbers DL. Receptor guanylyl cyclases. J Clin Invest 1992; 90:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19988/abstract/6\">",
"      Schulz S, Waldman SA. The guanylyl cyclase family of natriuretic peptide receptors. Vitam Horm 1999; 57:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19988/abstract/7\">",
"      Berridge MJ. Inositol trisphosphate and calcium signalling. Nature 1993; 361:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19988/abstract/8\">",
"      Bastl CP, Hayslett JP. The cellular action of aldosterone in target epithelia. Kidney Int 1992; 42:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19988/abstract/9\">",
"      Funder JW. Mineralocorticoids, glucocorticoids, receptors and response elements. Science 1993; 259:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19988/abstract/10\">",
"      Snyder HM, Noland TD, Breyer MD. cAMP-dependent protein kinase mediates hydrosmotic effect of vasopressin in collecting duct. Am J Physiol 1992; 263:C147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19988/abstract/11\">",
"      Clapham DE, Neer EJ. New roles for G-protein beta gamma-dimers in transmembrane signalling. Nature 1993; 365:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19988/abstract/12\">",
"      Duda T, Goraczniak RM, Sharma RK. Site-directed mutational analysis of a membrane guanylate cyclase cDNA reveals the atrial natriuretic factor signaling site. Proc Natl Acad Sci U S A 1991; 88:7882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19988/abstract/13\">",
"      Light DB, Corbin JD, Stanton BA. Dual ion-channel regulation by cyclic GMP and cyclic GMP-dependent protein kinase. Nature 1990; 344:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19988/abstract/14\">",
"      Abramow M, Beauwens R, Cogan E. Cellular events in vasopressin action. Kidney Int Suppl 1987; 21:S56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19988/abstract/15\">",
"      H&eacute;bert RL, Jacobson HR, Breyer MD. PGE2 inhibits AVP-induced water flow in cortical collecting ducts by protein kinase C activation. Am J Physiol 1990; 259:F318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19988/abstract/16\">",
"      Denis M, Poellinger L, Wikst&ouml;m AC, Gustafsson JA. Requirement of hormone for thermal conversion of the glucocorticoid receptor to a DNA-binding state. Nature 1988; 333:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19988/abstract/17\">",
"      Brown AJ, Finch J, Grieff M, et al. The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology 1993; 133:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19988/abstract/18\">",
"      Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene. Science 1996; 273:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19988/abstract/19\">",
"      Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19988/abstract/20\">",
"      Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19988/abstract/21\">",
"      Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol 1999; 17:1939.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7288 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-118.97.94.19-90DFCF4173-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_33_19988=[""].join("\n");
var outline_f19_33_19988=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS OF HORMONE ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Adenylyl cyclase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Guanylyl cyclase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Phosphatidylinositol turnover",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RNA transcription",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7288\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7288|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/61/10192\" title=\"figure 1\">",
"      Hormones renal circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/30/17902\" title=\"figure 2\">",
"      Adenylyl cyclase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/31/19966\" title=\"figure 3\">",
"      Phosphatidylinositol turnover",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/61/5086\" title=\"figure 4\">",
"      Steroid hormone action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=related_link\">",
"      Chapter 6B: Antidiuretic hormone and water balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41576?source=related_link\">",
"      Managing the side effects of tamoxifen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_33_19989="Aspirin and diphenhydramine: Patient drug information";
var content_f19_33_19989=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Aspirin and diphenhydramine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/54/33636?source=see_link\">",
"     see \"Aspirin and diphenhydramine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6816563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bayer&reg; PM [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10024849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give children and teenagers aspirin for flu signs or chickenpox.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sleep problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700954",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give to a child younger than 12 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701555",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to aspirin, diphenhydramine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 24 weeks pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man with problems passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697356",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you start on a low-salt diet, tell your doctor. It will change the way your body handles the lithium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain or heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ringing in ears.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695837",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 30 to 60 minutes before bedtime if using for sleep. Do not take for more than 2 weeks in a row.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694661",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Melt the effervescent tablet in",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        2",
"       </sub>",
"       cup of water. Do not swallow the tablet whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow caplets whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12099 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-06EB330AA9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_33_19989=[""].join("\n");
var outline_f19_33_19989=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6816563\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024849\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024851\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024850\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024855\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024856\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024858\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024853\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024854\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024859\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024860\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/54/33636?source=related_link\">",
"      Aspirin and diphenhydramine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_33_19990="Pancuronium: Drug information";
var content_f19_33_19990=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pancuronium: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/24/34179?source=see_link\">",
"    see \"Pancuronium: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/0/34821?source=see_link\">",
"    see \"Pancuronium: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2980447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pancuronium Bromide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F206183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Neuromuscular Blocker Agent, Nondepolarizing",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F206142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer I.V.; dose to effect; doses will vary due to interpatient variability; use ideal body weight for obese patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Surgery:",
"     </b>",
"     Initial: 0.06-0.1 mg/kg or 0.05 mg/kg after initial dose of succinylcholine for intubation; maintenance dose: 0.01 mg/kg administered 60-100 minutes after initial dose and then 0.01 mg/kg every 25-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Pretreatment/priming:",
"     </i>",
"     10% of intubating dose given 3-5 minutes before intubating dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      ICU paralysis (eg, facilitate mechanical ventilation) in select adequately sedated patients:",
"     </b>",
"     0.06-0.1 mg/kg bolus followed by 1-2 mcg/kg/minute (Murray, 2002)",
"     <b>",
"      or",
"     </b>",
"     0.1-0.2 mg/kg every 1-3 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F206162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/0/34821?source=see_link\">",
"      see \"Pancuronium: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infants &gt;1 month and Children: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F206143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F206144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Elimination half-life is doubled, plasma clearance is reduced, and rate of recovery is sometimes much slower.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 50% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Do not use.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F206145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Elimination half-life is doubled, plasma clearance is doubled, recovery time is prolonged, volume of distribution is increased (50%) and results in a slower onset, higher total dosage, and prolongation of neuromuscular blockade. Patients with liver disease may develop slow resistance to nondepolarizing muscle relaxant. Large doses may be required and problems may arise in antagonism.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F206121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as bromide: 1 mg/mL (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F206107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F206124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered undiluted by rapid I.V. injection",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F206189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Aminophylline, amiodarone, caffeine citrate, calcium gluconate, cefazolin, cefuroxime, cimetidine, diltiazem, dobutamine, dopamine, epinephrine, esmolol, etomidate, fenoldopam, fentanyl, fluconazole, gentamicin, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, isoproterenol, labetalol, levofloxacin, lorazepam, magnesium sulfate, midazolam, milrinone, morphine, nitroglycerin, nitroprusside, potassium chloride, procainamide, ranitidine, sodium bicarbonate, trimethoprim/sulfamethoxazole, vancomycin.",
"     <b>",
"      Incompatible",
"     </b>",
"     Diazepam, pantoprazole, thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Propofol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Caffeine citrate, heparin, hydrocortisone, meperidine, methohexital, neostigmine, promethazine, succinylcholine, thiopental.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F206122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Facilitation of  endotracheal intubation and relaxation of skeletal muscles during surgery; facilitation of  mechanical ventilation in ICU patients; does not relieve pain or produce sedation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F206191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       United States Pharmacopeia (USP) 2006: The Interdisciplinary Safe Medication Use Expert Committee of the USP has recommended the following:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       - Hospitals, clinics, and other practice sites should institute special safeguards in the storage, labeling, and use of these agents and should include these safeguards in staff orientation and competency training.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       - Healthcare professionals should be on high alert (especially vigilant) whenever a neuromuscular-blocking agent (NMBA) is stocked, ordered, prepared, or administered.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F206181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Elevation in pulse rate, elevated blood pressure and cardiac output, tachycardia, edema, skin flushing, circulatory collapse",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash, itching, erythema, burning sensation along the vein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Excessive salivation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Profound muscle weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Wheezing, bronchospasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Acute quadriplegic myopathy syndrome (prolonged use), anaphylactoid reactions, anaphylaxis, myositis ossificans (prolonged use)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F206127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pancuronium, bromide, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F206111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular cross-sensitivity: Cross-sensitivity with other neuromuscular-blocking agents may occur; use extreme caution in patients with previous anaphylactic reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Burn injury: Resistance may occur in burn patients (&gt;30% of body) for period of 5-70 days postinjury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conditions which may antagonize neuromuscular blockade: Alkalosis, hypercalcemia, demyelinating lesions, peripheral neuropathies, denervation, infection, muscle trauma, and diabetes mellitus may result in antagonism of neuromuscular blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conditions which may potentiate neuromuscular blockade: Electrolyte abnormalities, severe hyponatremia, severe hypocalcemia, severe hypokalemia, hypermagnesemia, neuromuscular diseases, acidosis, acute intermittent porphyria, Eaton-Lambert syndrome, myasthenia gravis, renal failure, and hepatic failure may result in potentiation of neuromuscular blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;Hepatic impairment: Use with caution in patients with hepatic impairment; adjust dose appropriately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; adjust dose appropriately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly, effects and duration are more variable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immobilized patients: Resistance may occur in patients who are immobilized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Some dosage forms may contain benzyl alcohol which has been associated with &ldquo;gasping syndrome&rdquo; in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Maintenance of an adequate airway and respiratory support is critical.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced personnel:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered by adequately trained individuals familiar with its use.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F206115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Neuromuscular-Blocking Agents may enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Neuromuscular-Blocking Agents (Nondepolarizing) may enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lincosamide Antibiotics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Polymyxin B: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procainamide: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May enhance the adverse/toxic effect of Pancuronium. Theophylline Derivatives may diminish the neuromuscular-blocking effect of Pancuronium. Management: Pancuronium dosage adjustment may be necessary to induce paralysis  in patients receiving concomitant theophylline derivatives. Monitor closely for adverse effects (e.g., cardiac effects) with concomitant use of these agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F206117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13494861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Small amounts of pancuronium cross the placenta (Daily, 1984). May be used short-term in cesarean section; reduced doses recommended in patients also receiving magnesium sulfate due to enhanced effects.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Pancuronium Bromide Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (10 mL): $3.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (2 mL): $3.98",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F206119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, blood pressure, assisted ventilation status; cardiac monitor, blood pressure monitor, and ventilator required",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alpax (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Bromurex (CO);",
"     </li>",
"     <li>",
"      Curon-B (ZA);",
"     </li>",
"     <li>",
"      Pancuron (PY);",
"     </li>",
"     <li>",
"      Pancuronio (CO);",
"     </li>",
"     <li>",
"      Pancuronium (PL);",
"     </li>",
"     <li>",
"      Pancuronium Bromide (AU);",
"     </li>",
"     <li>",
"      Pavulon (AE, AR, AT, AU, BD, BE, BG, BH, BR, CH, CL, CN, CY, CZ, DE, DK, EE, EG, ES, FI, FR, GB, GR, HK, HN, HR, HU, ID, IE, IN, IQ, IR, IT, JO, JP, KP, KW, LB, LU, LY, MT, MY, NL, NO, OM, PH, PK, PL, PT, QA, RU, SA, SE, SG, SK, SY, TH, TR, TW, VE, YE);",
"     </li>",
"     <li>",
"      Pavulone (IL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F206110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks neural transmission at the myoneural junction by binding with cholinergic receptor sites",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F206126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of effect: Peak effect: I.V.: 2-3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration (dose dependent): 60-100 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (30% to 45%); active metabolite 3-hydroxypancuronium (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     to",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     the activity of parent drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 110 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (55% to 70% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dailey PA, Fisher DM, Shnider SM, et al, \"Pharmacokinetics, Placental Transfer, and Neonatal Effects of Vecuronium and Pancuronium Administered During Cesarean Section,\"",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1984, 60(6):569-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/33/19990/abstract-text/6145374/pubmed\" id=\"6145374\" target=\"_blank\">",
"        6145374",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2008, 34(1):17-60. Available at",
"      <a href=\"file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616/pdf/134_2007_Article_934.pdf\" target=\"_blank\">",
"       file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616/pdf/134_2007_Article_934.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/33/19990/abstract-text/18058085/pubmed\" id=\"18058085\" target=\"_blank\">",
"        18058085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/33/19990/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meretoja OA, Taivainen T, Jalkanen L, et al, &ldquo;Synergism Between Atracurium and Vecuronium in Infants and Children During Nitrous Oxide-Oxygen-Alfentanil Anaesthesia,&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1994, 73(5):605-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/33/19990/abstract-text/7826787/pubmed\" id=\"7826787\" target=\"_blank\">",
"        7826787",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murray MJ, Cowen J, DeBlock H, et al, &ldquo;Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient. Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists, American College of Chest Physicians,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2002, 30(1):142-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/33/19990/abstract-text/11902255/pubmed\" id=\"11902255\" target=\"_blank\">",
"        11902255",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9738 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-CCB85E928E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_33_19990=[""].join("\n");
var outline_f19_33_19990=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709194\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2980447\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206183\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206142\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206162\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206143\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206144\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206145\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206121\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206107\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206124\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206189\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206122\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206191\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206181\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206127\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206111\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299816\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206115\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206117\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13494861\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323611\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206119\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038717\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206110\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206126\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9738\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9738|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/24/34179?source=related_link\">",
"      Pancuronium: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/0/34821?source=related_link\">",
"      Pancuronium: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_33_19991="Isotretinoin: Pediatric drug information";
var content_f19_33_19991=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Isotretinoin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"    see \"Isotretinoin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/34/33318?source=see_link\">",
"    see \"Isotretinoin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F185177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Absorica&trade;;",
"     </li>",
"     <li>",
"      Amnesteem&reg;;",
"     </li>",
"     <li>",
"      Claravis&trade;;",
"     </li>",
"     <li>",
"      Myorisan&trade;;",
"     </li>",
"     <li>",
"      Sotret&reg;;",
"     </li>",
"     <li>",
"      Zenatane&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F185178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Accutane&reg;;",
"     </li>",
"     <li>",
"      Clarus&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1048091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Acne Products",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Miscellaneous",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Retinoic Acid Derivative",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vitamin A Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1048084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"      see \"Isotretinoin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Acne vulgaris, severe recalcitrant nodular:",
"     </b>",
"     Children &ge;12 years and Adolescents: Oral: 0.5-1 mg/kg/day in 2 divided doses; for severe cases (involving trunk, nuchal region, lower back, buttocks, thighs) may require higher doses up to 2 mg/kg/day in 2 divided doses. Duration of therapy is typically 15-20 weeks or until the total cyst count decreases by 70%, whichever is sooner; an alternate reported approach is continuation until a total cumulative dose of 120 mg/kg (eg, 1 mg/kg/day for 120 days). An initial dose of &le;0.5 mg/kg/day may be used to minimize initial flaring (Strauss, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Acne vulgaris, moderate:",
"     </b>",
"     Limited data available: Children &ge;12 years and Adolescents: 20 mg/day  (~0.3-0.5 mg/kg/day) continued for 6-12 months to cumulative dose 120 mg/kg has been shown effective (Amichai, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Neuroblastoma, maintenance:",
"     </b>",
"     Children &ge;1 year and Adolescents: Oral: 160 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 2 divided doses for 14 consecutive days in a 28-day cycle for 6 cycles; begin after continuation chemotherapy or transplantation (Matthay, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Acne vulgaris:",
"     </b>",
"     Oral: 0.5-1 mg/kg/day in 2 divided doses for 15-20 weeks or until the total cyst count decreases by 70%, whichever is sooner. Adults with very severe disease/scarring or primarily involves the trunk may require dosage adjustment up to 2 mg/kg/day. A second course of therapy may be initiated after a period of &ge;2 months of therapy. An initial dose of &le;0.5 mg/kg/day may be used to minimize initial flaring (Strauss, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Children, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic impairment prior to treatment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatotoxicity during treatment: Liver enzymes may normalize with dosage reduction or with continued treatment; discontinue if normalization does not readily occur or if hepatitis is suspected.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F185155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Absorica&trade;: 10 mg, 20 mg, 30 mg, 40 mg [contains soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Claravis&trade;: 10 mg, 20 mg, 30 mg, 40 mg [contains soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Myorisan&trade;: 10 mg, 20 mg, 40 mg [contains soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amnesteem&reg;: 10 mg, 20 mg, 40 mg [contains soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sotret&reg;: 10 mg, 20 mg, 30 mg, 40 mg [contains parabens, soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zenatane&trade;: 10 mg, 20 mg, 40 mg [contains soybean oil]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F185139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11234007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a requirement of the REMS program, access to this medication is restricted. All patients (male and female), prescribers, wholesalers, and dispensing pharmacists must register and be active in the iPLEDGE&trade; risk management program, designed to eliminate fetal exposures to isotretinoin. This program covers all isotretinoin products (brand and generic). The iPLEDGE&trade; program requires that all patients meet qualification criteria and monthly program requirements (eg, pregnancy testing). Healthcare providers can only prescribe a maximum 30-day supply at each monthly visit and must counsel patients on the iPLEDGE&trade; program requirements and confirm counseling via the iPLEDGE&trade; automated system. Registration, activation, and additional information are provided at www.ipledgeprogram.com or by calling 866-495-0654.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Absorica&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM306859.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM306859.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Accutane&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085812.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085812.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Sotret&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089135.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089135.pdf`",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1048095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer orally with a meal (except Absorica&trade; which may be taken without regard to meals). According to the manufacturers&rsquo; labeling, capsules should be swallowed whole with a full glass of liquid. For patients  unable to swallow capsule whole, an oral liquid may be prepared; may irritate esophagus if contents are removed from the capsule.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1048087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;margin-right:2em;\">",
"     Absorica&reg;: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F), excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light.",
"    </p>",
"    <p style=\"text-indent:0em;margin-right:2em;\">",
"     Accutane&reg;: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1048094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of severe recalcitrant nodular acne unresponsive to conventional therapy, including systemic antibiotics (FDA approved in ages &ge;12 years and adults); has also been used  for the treatment of moderate acne and high-risk neuroblastoma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F185227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Accutane&reg; may be confused with Accolate&reg;, Accupril&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Claravis&trade; may be confused with Cleviprex&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ISOtretinoin may be confused with tretinoin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;\">",
"       Isotretinoin may be confused with tretinoin (which is also called all-",
"       <i>",
"        trans",
"       </i>",
"       retinoic acid, or ATRA ); while both products may have uses in cancer treatment, they are",
"       <b>",
"        not",
"       </b>",
"       interchangeable.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F185224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, edema, flushing, palpitation, stroke, syncope, tachycardia, vascular thrombotic disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Aggressive behavior, depression, dizziness, drowsiness, emotional instability, fatigue, headache, insomnia, lethargy, malaise, nervousness, paresthesia, pseudotumor cerebri, psychosis, seizure, stroke, suicidal ideation, suicide attempts, suicide, violent behavior",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Abnormal wound healing acne fulminans, alopecia, bruising, cheilitis, cutaneous allergic reactions, dry nose, dry skin, eczema, eruptive xanthomas, facial erythema, fragility of skin, hair abnormalities, hirsutism, hyperpigmentation, hypopigmentation, increased sunburn susceptibility, nail dystrophy, paronychia, peeling of palms, peeling of soles, photoallergic reactions, photosensitizing reactions, pruritus, purpura, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Abnormal menses, blood glucose increased, cholesterol increased, HDL decreased, hyperuricemia, triglycerides increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Bleeding and inflammation of the gums, colitis, esophagitis, esophageal ulceration, inflammatory bowel disease, nausea, nonspecific gastrointestinal symptoms, pancreatitis, weight loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Nonspecific urogenital findings",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis (rare), anemia, neutropenia, pyogenic granuloma, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, AST increased, GGTP increased, hepatitis, LDH increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, arthritis, back pain, bone abnormalities, bone mineral density decreased, calcification of tendons and ligaments, CPK increased, myalgia, premature epiphyseal closure, skeletal hyperostosis, tendonitis, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blepharitis, cataracts, chalazion, color vision disorder, conjunctivitis, corneal opacities, eyelid inflammation, hordeolum, keratitis, night vision decreased, optic neuritis, photophobia, visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing impairment, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Glomerulonephritis, hematuria, proteinuria, pyuria, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasms, epistaxis, respiratory infection, voice alteration, Wegener's granulomatosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, anaphylactic reactions, disseminated herpes simplex, diaphoresis, infection, lymphadenopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abnormal meibomian gland secretion, erythema multiforme, meibomian gland atrophy, myopia, pseudotumor cerebri, Stevens-Johnson syndrome, toxic epidermal necrolysis, visual acuity decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1048098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to isotretinoin, parabens, vitamin A or other retinoids; patients who are pregnant or intend to become pregnant during treatment",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1048083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with diabetes mellitus; impaired glucose control has been reported. Children may experience a higher frequency of some adverse effects including arthralgia (22%) and back pain (29%). This medication should only be prescribed by prescribers competent in treating severe recalcitrant nodular acne and experienced with the use of systemic retinoids. Safety of long-term use is not established and is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1048082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     . Isotretinoin must not be used by female patients who are or may become pregnant",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; birth defects [CNS (cerebral abnormalities, hydrocephalus, microcephaly, cranial nerve deficit, cerebellar malformation), skull, ear, eye, and cardiovascular systems, cleft palate, thymus and parathyroid gland abnormalities] have been noted following isotretinoin exposure during pregnancy and the risk for severe birth defects is high, with any dose or even with short treatment duration. Low IQ scores have been reported. The risk for spontaneous abortion and premature births is increased. Because of the high likelihood of teratogenic effects, all patients (male and female), prescribers, wholesalers, and dispensing pharmacists must register and be active in the iPLEDGE risk evaluation and mitigation strategy (REMS) program",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .  Prescription for isotretinoin should not be issued until a female patient has had negative results from two urine or serum pregnancy tests, one performed in the prescriber's office when the patient is qualified for therapy, the second one performed on the second day of next normal menstrual period or 11 days after the last unprotected act of sexual intercourse, whichever is later. Pregnancy testing and counseling should be repeated monthly. Two forms of effective contraception must be used for at least 1 month before beginning therapy, during therapy, and for 1 month after discontinuation of therapy. Upon discontinuation of treatment, females of childbearing potential should have a pregnancy test after their last dose and again 1 month after their last dose. If pregnancy occurs during treatment, isotretinoin should be discontinued immediately and patient should be referred to a physician experienced in reproductive toxicity. Patients should be instructed not to donate blood during therapy and for 1 month following discontinuation of therapy due to risk of donated blood being given to a pregnant female.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Isotretinoin may cause depression, psychosis, aggressive or violent behavior, and changes in mood; rarely, suicidal thoughts and actions have been reported with isotretinoin use. All patients should be observed closely for symptoms of depression or suicidal thoughts; discontinuation of treatment alone may not be sufficient; further evaluation may be necessary; use with extreme caution in patients with a history of psychiatric disorder.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Retinoids have been associated with pseudotumor cerebri (benign intracranial hypertension), especially in children. Concurrent use of other drugs associated with this effect (eg, tetracyclines) may increase risk. Early signs and symptoms include papilledema, headache, nausea, vomiting, and visual disturbances; discontinue if papilledema occurs. Rare postmarketing cases of severe skin reactions (eg, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis), including fatalities, have been reported; monitor for severe skin reactions; discontinue use if severe skin reaction occurs. Anaphylaxis and other types of allergic reactions, including cutaneous reactions and allergic vasculitis, have been reported.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Dose-related elevations of serum triglycerides (in excess of 800 mg/dL) have been reported with use; acute pancreatitis and fatal hemorrhagic pancreatitis (rare) have been reported; discontinue therapy if severe hypertriglyceridemia or symptoms of pancreatitis occur; use with caution in patients with or history of hypertriglyceridemia. Clinical hepatitis and elevated liver enzymes have been reported with use; may require interruption of therapy until etiology is determined. Inflammatory bowel disease has been reported with use; discontinue treatment if abdominal pain, rectal bleeding, or severe diarrhea occurs.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May decrease bone mineral density; osteoporosis, osteopenia, and bone fractures have been reported with long-term, high-dose, or multiple courses of therapy. Use with caution in patients with a genetic predisposition to bone disorders (ie, osteoporosis, osteomalacia), with disease states that can induce bone disorders including patients with anorexia nervosa or in patients receiving drugs that cause osteoporosis/osteomalacia or affect vitamin D metabolism (ie, corticosteroids, anticonvulsants. Patients may be at risk when participating in activities with repetitive impact (eg, sports). Skeletal hyperostosis, calcification of ligaments and tendons, and premature epiphyseal closure have also been reported with the use.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Vision impairment, corneal opacities, decreased tolerance to contact lenses (due to dry eyes), and decreased night vision have  been reported with use. Hearing impairment has occurred, which may persist after therapy is discontinued; discontinue therapy if hearing impairment or tinnitus develops.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Absorica&trade; absorption is ~83% greater than Accutane&reg; when administered under fasting conditions; they are bioequivalent when taken with a high-fat meal. Absorica&trade; is not interchangeable with other generic isotretinoin products. Some formulation may contain soybean oil. Isotretinoin and tretinoin (also known as ATRA) may be confused; while both products may be used in cancer treatment, they are",
"     <b>",
"      not",
"     </b>",
"     interchangeable; verify product prior to dispensing and administration to prevent medication errors.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F185148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of ISOtretinoin. Specifically, the risk for elevated triglyceride concentrations may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Retinoic Acid Derivatives may diminish the therapeutic effect of Contraceptives (Estrogens). Two forms of contraception are recommended in females of child-bearing potential during retinoic acid derivative therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Retinoic Acid Derivatives may diminish the therapeutic effect of Contraceptives (Progestins). Retinoic Acid Derivatives may decrease the serum concentration of Contraceptives (Progestins).  Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: ISOtretinoin may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin A: Retinoic Acid Derivatives may enhance the adverse/toxic effect of Vitamin A.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1048100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food (high-fat meal) or milk increases isotretinoin bioavailability except Absorica&trade;. Limit intake of vitamin A; avoid use of other vitamin A products.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F185150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F185163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Major fetal abnormalities (both internal and external), spontaneous abortion and premature births  have been reported.",
"     <b>",
"      [U.S. Boxed Warnings]: Birth defects (facial, eye, ear, skull, central nervous system, cardiovascular, thymus and parathyroid gland abnormalities) have been noted following isotretinoin exposure during pregnancy and the risk for severe birth defects is high, with any dose or even with short treatment duration. Low IQ scores have also been reported. The risk for spontaneous abortion and premature births is increased. Because of the high likelihood of teratogenic effects, all patients (male and female), prescribers, wholesalers, and dispensing pharmacists must register and be active in the iPLEDGE&trade; risk evaluation and mitigation strategy (REMS) program; do not prescribe isotretinoin for women who are or who are likely to become pregnant while using the drug. If pregnancy occurs during therapy, isotretinoin should be discontinued immediately and the patient referred to an obstetrician-gynecologist specializing in reproductive toxicity.",
"     </b>",
"     This medication is contraindicated in females of childbearing potential unless they are able to comply with the guidelines of the iPLEDGE&trade; pregnancy prevention program. Females of childbearing potential should not become pregnant during therapy or for 1 month following discontinuation of isotretinoin. Upon discontinuation of treatment, females of childbearing potential should have a pregnancy test after their last dose and again one month after their last dose. Two forms of contraception should be continued during this time. Any pregnancies should be reported to the iPLEDGE&trade; program (www.ipledgeprogram.com or 866-495-0654).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1048090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count, baseline sedimentation rate, glucose, CPK; signs of depression, mood alteration, psychosis, aggression, severe skin reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pregnancy test (for all female patients of childbearing potential): Two negative tests with a sensitivity of at least 25 mIU/mL prior to beginning therapy (the second performed at least 19 days after the first test and performed during the first 5 days of the menstrual period immediately preceding the start of therapy); monthly tests to rule out pregnancy prior to refilling prescription",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lipids: Prior to treatment and at weekly or biweekly intervals until response to treatment is established. Test should not be performed &lt;36 hours after consumption of ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liver function tests: Prior to treatment and at weekly or biweekly intervals until response to treatment is established.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1048081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduces sebaceous gland size and reduces sebum production in acne treatment; regulates cell proliferation and differentiation in neuroblastoma",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1048097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Pharmacokinetic parameters in adolescents (12-15 years) are similar to adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Enhanced with a high-fat meal; Absorica&trade; absorption is ~83% greater than Accutane&reg; when administered under fasting conditions; they are bioequivalent when taken with a high-fat meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99% to 100%; primarily albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP2B6, 2C8, 2C9, 2D6, 3A4; forms metabolites; major metabolite: 4-oxo-isotretinoin (active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, terminal: Parent drug: 21 hours; Metabolite: 21-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Fasting conditions: Within 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine and feces (equal amounts)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1048089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/34/33318?source=see_link\">",
"      see \"Isotretinoin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A patient information/consent form must be signed before this medication can be prescribed. Prescriptions will be written for a 1-month supply and must be filled within 7 days; they will not be honored if filled after that time or if they do not have the appropriate yellow qualification sticker attached. Read the patient Medication Guide received with each prescription and refill of isotretinoin. Do not take vitamin supplements containing vitamin A; use caution when driving at night since decreased night vision can develop suddenly; patients who wear contact lenses may experience decreased tolerance to the lenses; avoid alcohol; may cause dry mouth; notify physician of any headache, blurred vision, yellowing of skin or eyes, bone or muscle pain, vision changes, suicidal thoughts, dark urine, abdominal pain, rectal bleeding, severe diarrhea, or rashes. This drug should not be used during pregnancy; female patients of childbearing potential must be counseled to use two effective forms of contraception simultaneously; microdosed progesterone products that do not contain an estrogen (&ldquo;mini-pills&rdquo;) are not an acceptable form of contraception during isotretinoin treatment; monthly tests to rule out pregnancy are required during therapy. Do not self-medicate with St John's wort due to a possible interaction with hormonal contraceptives. Inform prescriber if  pregnant. Do not get pregnant 1 month before, during, or for 1 month following therapy. It is important to note that any type of contraception may fail; it is the responsibility of the patient to be compliant with contraceptive therapy. Do not breast-feed. Do not donate blood during therapy and for 1 month following discontinuation of therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F5935063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent: Use appropriate precautions for handling and disposal of teratogenic capsule contents.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For patients unable to swallow the capsules whole, an oral liquid may be prepared with softgel capsules (not recommended by the manufacturers) by one of the following methods:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Place capsules (softgel formulations only) in small container and add warm (~37&deg;C [97&deg;F]) water or milk to cover capsule(s); wait 2-3 minutes until capsule is softened and then drink the milk or water with the softened capsule, or swallow softened capsule.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Puncture capsule (softgel formulations only) with needle or cut with scissors; squeeze capsule contents into 5-10 mL of milk or tube feed formula; draw mixture up into oral syringe and administer via feeding tube; flush feeding tube with &ge;30 mL additional milk or tube feeding formula.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Puncture capsule (softgel formulations only) with needle or cut with scissors and draw contents into oral syringe; add 1-5 mL of medium chain triglyceride, soybean, or safflower oil to the oral syringe; mix gently and administer via feeding tube; flush feeding tube with &ge;30 mL milk or tube feeding formula.",
"    </p>",
"    <div class=\"reference\">",
"     Lam MS, \"Extemporaneous Compounding of Oral Liquid Dosage Formulations and Alternative Drug Delivery Methods for Anticancer Drugs,\"",
"     <i>",
"      Pharmacotherapy",
"     </i>",
"     , 2011, 31(2):164-92.",
"     <span class=\"pubmed-id\">",
"      21275495",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, &ldquo;Retinoid Therapy for Severe Dermatological Disorders,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1992, 90(1 Pt 1):119-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/33/19991/abstract-text/1535432/pubmed\" id=\"1535432\" target=\"_blank\">",
"        1535432",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Amichai B, Shemer A, and Grunwald MH, \"Low-Dose Isotretinoin in the Treatment of Acne Vulgaris,\"",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2006, 54(4):644-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/33/19991/abstract-text/16546586/pubmed\" id=\"16546586\" target=\"_blank\">",
"        16546586",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brecher AR and Orlow SJ, \"Oral Retinoid Therapy for Dermatologic Conditions in Children and Adolescents,\"",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2003, 49(2):171-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/33/19991/abstract-text/12894062/pubmed\" id=\"12894062\" target=\"_blank\">",
"        12894062",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DiGiovanna JJ and Peck GL, &ldquo;Oral Synthetic Retinoid Treatment in Children,&rdquo;",
"      <i>",
"       Pediatr Dermatol",
"      </i>",
"      , 1983, 1(1):77-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/33/19991/abstract-text/ 6238291 /pubmed\" id=\" 6238291 \" target=\"_blank\">",
"        6238291",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Matthay KK, Villablanca JG, Seeger RC, et al, &ldquo;Treatment of High-Risk Neuroblastoma With Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid. Children's Cancer Group,&rdquo;",
"      <i>",
"       N Engl J Med,",
"      </i>",
"      1999, 341:1165-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/33/19991/abstract-text/10519894/pubmed\" id=\"10519894\" target=\"_blank\">",
"        10519894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reynolds CP, Kane DJ, Einhorn PA, et al, &ldquo;Response of Neuroblastoma to Retinoic Acid",
"      <i>",
"       In Vitro",
"      </i>",
"      , and",
"      <i>",
"       In Vivo",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       Prog Clin Biol Res",
"      </i>",
"      , 1991, 366:203-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/33/19991/abstract-text/2068138/pubmed\" id=\"2068138\" target=\"_blank\">",
"        2068138",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Strauss JS, Krowchuk DP, Leyden JJ, et al, \"Guidelines of Care for Acne Vulgaris Management,\"",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2007, 56(4):651-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/33/19991/abstract-text/17276540/pubmed\" id=\"17276540\" target=\"_blank\">",
"        17276540",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13395 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-294E67EF58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_33_19991=[""].join("\n");
var outline_f19_33_19991=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708957\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185177\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185178\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048091\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048084\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185155\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185139\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234007\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874644\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048095\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048087\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048094\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185227\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185224\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048098\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048083\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048082\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299550\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185148\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048100\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185150\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185163\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048090\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048081\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048097\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048089\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5935063\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13395\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13395|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=related_link\">",
"      Isotretinoin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/34/33318?source=related_link\">",
"      Isotretinoin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_33_19992="Tipranavir: Drug information";
var content_f19_33_19992=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tipranavir: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/46/20197?source=see_link\">",
"    see \"Tipranavir: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F786677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aptivus&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2935530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aptivus&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F786701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Protease Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F786734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     <b>",
"      HIV infection:",
"     </b>",
"     Oral: 500 mg twice daily;",
"     <b>",
"      Note:",
"     </b>",
"     Coadministration with ritonavir (200 mg twice daily) is required.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F6215184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      HIV infection:",
"     </b>",
"     Children &ge;2 years: Oral: 14 mg/kg or 375 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (maximum: 500 mg/dose) twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     Coadministration with ritonavir (6 mg/kg or 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     [maximum: 200 mg/dose] twice daily) is required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     If intolerance or toxicity develops and virus is not resistant to multiple protease inhibitors: May decrease dose to 12 mg/kg or 290 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     Coadministration with ritonavir (5 mg/kg or 115 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice daily) is required.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F786735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F786736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     No adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F4303416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Mild impairment (Child-Pugh class A): No adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Moderate-to-severe impairment (Child-Pugh class B or C): Concurrent use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F786742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, soft gelatin, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aptivus&reg;: 250 mg [contains dehydrated ethanol 7%/capsule]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aptivus&reg;: 100 mg/mL (95 mL) [contains propylene glycol, vitamin E; buttermint-butter toffee flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F786679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F786738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Coadministration with ritonavir is required. Administer with ritonavir capsules or solution without regard to meals; administer with ritonavir tablets with meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F786703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Treatment of HIV-1 infections in combination with ritonavir and other antiretroviral agents; limited to highly treatment-experienced or multiprotease inhibitor-resistant patients.",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F786713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Rash (children 21%; adults 3% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypertriglyceridemia (&gt;400 mg/dL: 61%), hypercholesterolemia (&gt;300 mg/dL: 22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Transaminases increased (&gt;2.5 x ULN: 26% to 32%; grade 3/4: 10% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: CPK increased (grade 3/4: children 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Fever (6% to 8%), fatigue (6%), headache (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Nausea (5% to 9%), amylase increased (grade 3: 6% to 8%), vomiting (6%), abdominal pain (4%), diarrhea (children 4%), weight loss (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Hematologic: Bleeding (children 8%), WBC decreased (grades 3: 5%), anemia (3%), neutropenia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Hepatic: ALT increased (2%, grades 3/4: 10%), AST increased (grades 3/4: 6%), GGT increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Cough (children 6%), dyspnea (2%), epistaxis (children 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening): Abdominal distension, anorexia, appetite decreased, diabetes mellitus, dizziness, dyspepsia, exanthem, facial wasting, flatulence, flu-like syndrome, gastroesophageal reflux, hepatic failure, hepatic steatosis, hepatitis, hyperbilirubinemia, hyperglycemia, hypersensitivity, immune reconstitution syndrome, insomnia, intracranial hemorrhage, lipase increased, lipoatrophy, lipodystrophy (acquired), lipohypertrophy, malaise, mitochondrial toxicity, muscle cramp, neuropathy (peripheral), pancreatitis, pruritus, renal insufficiency, sleep disorder, somnolence, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F786708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Concurrent therapy of tipranavir/ritonavir with alfuzosin, amiodarone, bepridil, cisapride, ergot derivatives (eg, dihydroergotamine, ergonovine, ergotamine, methylergonovine), flecainide, lovastatin, midazolam (oral), pimozide, propafenone, quinidine, rifampin, sildenafil (for pulmonary arterial hypertension [eg, Revatio&reg;]), simvastatin, St John&rsquo;s wort, and triazolam; moderate-to-severe hepatic impairment (Child-Pugh class B or C)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F786709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: In combination with ritonavir, may cause hepatitis (including fatalities) and/or exacerbate pre-existing hepatic dysfunction (causal relationship not established); patients with chronic hepatitis B or C are at increased risk.",
"     </b>",
"     Monitor patients closely; discontinue use if signs or symptoms of toxicity occur or if asymptomatic AST/ALT elevations &gt;10 times upper limit of normal or AST/ALT elevations &gt;5-10 times upper limit of normal concurrently with total bilirubin &gt;2.5 times the upper limit of normal occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Protease inhibitors have been associated with a variety of hypersensitivity events (some severe), including rash, anaphylaxis (rare), angioedema, bronchospasm, erythema multiforme, and/or Stevens-Johnson syndrome (rare). It is generally recommended to discontinue treatment if severe rash or moderate symptoms accompanied by other systemic symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased cholesterol: Increases in total cholesterol and triglycerides have been reported; screening should be done prior to therapy and periodically throughout treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intracranial hemorrhage:",
"     <b>",
"      [U.S. Boxed Warning]: Use in combination with ritonavir has been associated with rare reports of fatal and nonfatal intracranial hemorrhage; causal relationship not established.",
"     </b>",
"     Events often occurred in patients with medical conditions (eg, CNS lesions, head trauma, recent neurosurgery, coagulopathy, alcohol abuse) or concurrent therapy which may have influenced these events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Use with caution in patients with sulfonamide allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Changes in glucose tolerance, hyperglycemia, exacerbation of diabetes, DKA, and new-onset diabetes mellitus have been reported in patients receiving protease inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemophilia A or B: Use with caution in patients with hemophilia A or B; increased bleeding during protease inhibitor therapy has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with mild hepatic impairment; contraindicated in moderate-to-severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Platelet aggregation: May impair platelet aggregation, resulting in bleeding; use with caution in patients who may be at risk for increased bleeding (trauma, surgery or other medical conditions).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Concomitant use of tipranavir with some drugs may require cautious use, may not be recommended, may require dosage adjustments, or may be contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F786718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (strong);",
"     <b>",
"      Induces",
"     </b>",
"     P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F786717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abacavir: Protease Inhibitors may decrease the serum concentration of Abacavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Tipranavir may enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: Protease Inhibitors may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ALPRAZolam: Protease Inhibitors may increase the serum concentration of ALPRAZolam.  Management: Concurrent use of alprazolam with indinavir is contraindicated.  All patients receiving such a combination should be monitored closely for excessive response to alprazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Protease Inhibitors may decrease the metabolism of Amiodarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Protease Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Tipranavir may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.  Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Tipranavir may increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bepridil [Off Market]: Tipranavir may increase the serum concentration of Bepridil [Off Market].",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Boceprevir. Management: Avoid initiating coadministration of boceprevir with ritonavir-boosted atazanavir, darunavir, or lopinavir. Monitor for reduced HIV and HCV infection responses when boceprevir is combined with any ritonavir-boosted HIV protease inhibitor regimen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Tipranavir. Tipranavir may increase the serum concentration of Bosentan. Management: Use bosentan 62.5 mg/day or every other day in adult patients taking tipranavir/ritonavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting tipranavir/ritonavir; wait at least 10 days before restarting bosentan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Increased serum concentrations of the calcium channel blocker may increase risk of AV nodal blockade.  Management: Avoid concurrent use when possible. If this combination is used, monitor for evidence of toxicity. The manufacturer of atazanavir recommends a 50% dose reduction for diltiazem be considered. Saquinavir or tipranavir use with bepridil is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Protease Inhibitors may increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically, certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite, which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.  Management: Avoid clarithromycin doses greater than 1000 mg/day when used with a protease inhibitor. Further dose reductions may be needed in patients with impaired renal function. Consider alternative antimicrobial for any non-MAC infection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Protease Inhibitors may decrease the serum concentration of Contraceptives (Estrogens).  Management: Use oral contraceptives containing at least 35mcg ethinyl estradiol with atazanavir/ritonavir, or no more than 30mcg in patients receiving atazanavir alone. Use of an alternative, non-hormonal contraceptive is recommended with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Strong) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible.  Closely monitor for decreased levels/effects of dabigatran if concomitantly administering  p-glycoprotein inducers, particularly strong inducers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Delavirdine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: Tipranavir may decrease the serum concentration of Didanosine.  Management: It is recommended that didanosine be administered at least 2 hours apart from tipranavir in order to minimize any potential dosage form-related interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May enhance the adverse/toxic effect of Tipranavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Protease Inhibitors may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enfuvirtide: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Enfuvirtide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Protease Inhibitors may decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Protease Inhibitors may increase the serum concentration of Ergot Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cabergoline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives. Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Tipranavir may decrease the serum concentration of Etravirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Tipranavir may increase the serum concentration of Flecainide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Tipranavir. Management: Limit fluconazole adult maximum dose to 200 mg/day in patients treated with tipranavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May decrease the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of Fusidic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Garlic: May decrease the serum concentration of Protease Inhibitors. Management: Concurrent use of garlic supplements with protease inhibitors is not recommended.  If this combination is used, monitor closely for altered serum concentrations/effects of protease inhibitors, and particularly for signs/symptoms of therapeutic failure.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Tipranavir may increase the serum concentration of Itraconazole.  Management: Limit itraconazole adult maximum dose to 200 mg/day in patients treated with tipranavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Tipranavir may increase the serum concentration of Ketoconazole (Systemic).  Management: Limit ketoconazole adult maximum dose to 200 mg/day in patients treated with tipranavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Protease Inhibitors may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Protease Inhibitors may enhance the adverse/toxic effect of Meperidine. Protease Inhibitors may decrease the serum concentration of Meperidine. Concentrations of the toxic Normeperidine metabolite may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Protease Inhibitors may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Systemic): May enhance the adverse/toxic effect of Tipranavir. A disulfiram-like reaction may occur due to the alcohol contained in tipranavir capsules.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Topical): May enhance the adverse/toxic effect of Tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Protease Inhibitors may increase the serum concentration of Midazolam.  Management: Oral midazolam contraindicated with all protease inhibitors.  IV midazolam contraindicated with fosamprenavir and nelfinavir; other protease inhibitors recommend caution, close monitoring, and consideration of lower IV midazolam doses with concurrent use.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nefazodone: Protease Inhibitors may increase the serum concentration of Nefazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Protease Inhibitors may decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Tipranavir may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of other Protease Inhibitors. Management: Atazanavir--indinavir combination contraindicated. Tipranavir/ritonavir or atazanavir/ritonavir not recommended with other protease inhibitors.  Other combos may require dose changes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: Tipranavir may decrease the serum concentration of Proton Pump Inhibitors. These data are derived from studies with Ritonavir-boosted Tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Protease Inhibitors may decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltegravir: Tipranavir may decrease the serum concentration of Raltegravir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: Tipranavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Tipranavir may increase the serum concentration of Rifabutin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Tipranavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosuvastatin: Protease Inhibitors may increase the serum concentration of Rosuvastatin.  Management: Start with the lowest possible rosuvastatin dose and monitor for signs/symptoms of toxicity. In adult patients receiving atazanavir/ritonavir or lopinavir/ritonavir, initiate rosuvastatin at a 5 mg/day and do not exceed a dose of 10 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Protease Inhibitors may increase the serum concentration of Sildenafil.  Management: Erectile dysfunction: sildenafil max = 25 mg/48 hrs with ritonavir, atazanavir, or darunavir; starting dose = 25 mg with other protease inhibitors (adult doses).  Contraindicated if sildenafil being used for pulmonary arterial hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Protease Inhibitors may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Protease Inhibitors may increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Tipranavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Protease Inhibitors may decrease the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Protease Inhibitors may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Protease Inhibitors may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased.  Management: Tetrabenazine adult dose should be reduced by 50% when starting a strong CYP2D6 inhibitor.  Maximum tetrabenazine adult dose is 50 mg/day when used with a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Protease Inhibitors may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: Tipranavir may increase the serum concentration of TraZODone.  Management: Consider using a lower dose of trazodone when used in combination with tipranavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triazolam: Protease Inhibitors may increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Protease Inhibitors may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Protease Inhibitors may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Protease Inhibitors may increase the serum concentration of Vardenafil.  Management: Limit vardenafil adult dose to max of 2.5 mg/72 hrs with ritonavir, atazanavir, or darunavir; limit to max adult dose of 2.5 mg/24 hrs with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: Tipranavir may enhance the adverse/toxic effect of Vitamin E. This interaction only applies to tipranavir oral solution.  Management: Patients taking tipranavir oral solution are advised to avoid taking additional vitamin E, beyond the amounts contained in a multivitamin product.  This interaction does not apply to tipranavir capsules.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Protease Inhibitors may decrease the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F786721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Capsules contain dehydrated alcohol 7% w/w (0.1 g per capsule)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John's wort may decrease the levels/effects of tipranavir/ritonavir. Vitamin E (high dose) may increase the risk of bleeding. Garlic may decrease the serum concentration of tipranavir. Management: Avoid St John's wort; concurrent use is contraindicated. Avoid vitamin E supplementation. Garlic supplementation is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F786704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F786705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies; fetotoxity was observed with some doses. Tipranavir crosses the human placenta. The DHHS Perinatal HIV Guidelines note there are insufficient data to recommend use during pregnancy; however, if used, tipranavir must be given with low-dose ritonavir boosting. A small increased risk of preterm birth has been associated with maternal use of protease inhibitor-based combination antiretroviral (ARV) therapy during pregnancy; however, the benefits of use generally outweigh this risk and protease inhibitors (PIs) should not be withheld if otherwise recommended. Hyperglycemia, new onset of diabetes mellitus, or diabetic ketoacidosis have been reported with PIs; it is not clear if pregnancy increases this risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum ARV drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV, also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Women receiving estrogen (as hormonal contraception or replacement therapy) may have an increased incidence of rash.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F786706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F786707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal or infant antiretroviral therapy does not completely eliminate the risk of postnatal HIV transmission. In addition, multiclass-resistant virus has been detected in breast-feeding infants despite maternal therapy. Therefore, in the United States, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, complete avoidance of breast-feeding by HIV-infected women is recommended to decrease potential transmission of HIV (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F786737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Capsule contains dehydrated ethanol. Oral solution formulation contains vitamin E; additional vitamin E supplements should be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F4589246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Aptivus Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (120): $1415.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Aptivus Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (95 mL): $471.73",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F786740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Viral load, CD4, serum glucose, liver function tests, bilirubin",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aptivus (AR, AT, AU, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IT, MT, MX, NL, NO, NZ, PL, PT, RU, SE, SK, TR, TW);",
"     </li>",
"     <li>",
"      Elodius (BR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F786724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Binds to the site of HIV-1 protease activity and inhibits cleavage of viral Gag-Pol polyprotein precursors into individual functional proteins required for infectious HIV. This results in the formation of immature, noninfectious viral particles.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F786726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Absorption: Incomplete (percentage not established)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 7.7-10 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Protein binding: &gt;99% (albumin, alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Metabolism: Hepatic, via CYP3A4 (minimal when coadministered with ritonavir)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Bioavailability: Not established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Half-life elimination: Children 2-&lt;6 years of age: ~8 hours, 6-&lt;12 years of age: ~7 hours, 12-18 years: ~5 hours; Adults: 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Time to peak, plasma: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Excretion: Feces (82%); urine (4%); primarily as unchanged drug (when coadministered with ritonavir)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\"  July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Graff J, von Hentig N, Kuczka, K, et al, &ldquo;Significant Effects of Tipranavir on Platelet Aggregation and Thromboxane B",
"      <sub>",
"       2",
"      </sub>",
"      Formation",
"      <i>",
"       in vitro",
"      </i>",
"      and",
"      <i>",
"       in vivo",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2008, 61(2):394-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/33/19992/abstract-text/18156609/pubmed\" id=\"18156609\" target=\"_blank\">",
"        18156609",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, &ldquo;Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,&rdquo; August 16, 2010. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9459 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.81.197.98-2E1E3D353B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_33_19992=[""].join("\n");
var outline_f19_33_19992=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708929\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786677\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2935530\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786701\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786734\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215184\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786735\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786736\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303416\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786742\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786679\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786738\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786703\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786713\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786708\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786709\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786718\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786717\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786721\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786704\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786705\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786706\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786707\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786737\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4589246\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786740\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869444\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786724\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786726\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9459\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9459|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/46/20197?source=related_link\">",
"      Tipranavir: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_33_19993="Phytophotodermatitis 2";
var content_f19_33_19993=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57871%7EDERM%2F81457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57871%7EDERM%2F81457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Phytophotodermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After making lemonade during an outdoor excursion trip, this 38-year-old female presented with erythematous linear and angulated patches and crusts on the face.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Shahbaz A Janjua, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Berloque dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This adolescent developed hyperpigmented streaks from a photosensitizer in his sunscreen. After several days of erythema, the red patches became dark brown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Kosman Sadek Zikry, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_33_19993=[""].join("\n");
var outline_f19_33_19993=null;
var title_f19_33_19994="Management of gastroesophageal reflux disease in children and adolescents";
var content_f19_33_19994=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of gastroesophageal reflux disease in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/33/19994/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/33/19994/contributors\">",
"     Harland S Winter, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/33/19994/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/33/19994/contributors\">",
"     William J Klish, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/33/19994/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/33/19994/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/33/19994/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The passage of gastric contents into the esophagus (gastroesophageal reflux) is a normal physiologic process that occurs in healthy infants, children, and adults. Most episodes are brief and do not cause symptoms, esophageal injury, or other complications. In contrast, gastroesophageal reflux disease (GERD) is present when the reflux episodes are associated with symptoms or complications. The range of symptoms and complications of GERD in children are variable depending upon the child's age.",
"   </p>",
"   <p>",
"    Several treatment options are available for controlling symptoms and preventing complications in children with GERD. The choice among them depends upon the patient's age, the type and severity of symptoms, and response to treatment.",
"   </p>",
"   <p>",
"    This topic review focuses on the management of GERD in children and adolescents. The clinical manifestations, diagnosis, and pathophysiology of GERD in this age group and issues related to GERD in infants are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30441?source=see_link\">",
"     \"Gastroesophageal reflux in infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23657?source=see_link\">",
"     \"Gastroesophageal reflux in premature infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These discussions are generally consistent with an official consensus statement and systematic review issued by the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) and European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/1\">",
"     1",
"    </a>",
"    ]. The full text of these guidelines is available at the NASPGHAN website (",
"    <a class=\"external\" href=\"file://www.naspghan.org/\">",
"     www.naspghan.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LIFESTYLE CHANGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of lifestyle changes that may be beneficial depend upon the patient's age and symptom characteristics. Few studies have focused on the benefit of lifestyle modifications in children and adolescents with gastroesophageal reflux disease (GERD) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, recommendations are mostly extrapolated from studies in adults. Even in adults, there is limited evidence supporting efficacy for these interventions, as is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link&amp;anchor=H2#H2\">",
"     \"Medical management of gastroesophageal reflux disease in adults\", section on 'Lifestyle modifications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following approaches have some benefit in adult patients with reflux, but have not been rigorously evaluated in either adults or children [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weight loss or weight management for individuals who are overweight",
"     </li>",
"     <li>",
"      Head of bed elevation is important for individuals with nocturnal or laryngeal symptoms, but its value for other situations is unclear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following lifestyle approaches also are used frequently. There is some evidence that these lifestyle changes improve laboratory measures of reflux (such as lower esophageal sphincter pressure), but no clinical evidence that they consistently improve reflux symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dietary modification &ndash; A practical approach is to avoid a core group of reflux-inducing foods, including chocolate, peppermint, and alcohol, which may reduce lower esophageal sphincter pressure. Acidic beverages, including colas with caffeine and orange juice also may exacerbate symptoms. The benefit of reducing fat intake in children is unproven.",
"     </li>",
"     <li>",
"      Avoiding the supine position soon after eating.",
"     </li>",
"     <li>",
"      Promotion of salivation by either chewing gum or using oral lozenges. Salivation neutralizes refluxed acid, thereby increasing the rate of esophageal acid clearance.",
"     </li>",
"     <li>",
"      Avoidance of tobacco (including passive exposure to tobacco smoke) and alcohol. Nicotine and alcohol reduce lower esophageal sphincter pressure, and smoking also diminishes salivation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are five main classes of drugs that have been evaluated for treatment of gastroesophageal reflux disease (GERD) (",
"    <a class=\"graphic graphic_table graphicRef55435 \" href=\"UTD.htm?12/0/12302\">",
"     table 1",
"    </a>",
"    ). Pharmacotherapy for gastroesophageal reflux in adults is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link&amp;anchor=H3#H3\">",
"     \"Medical management of gastroesophageal reflux disease in adults\", section on 'Acid suppressive medications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Proton pump inhibitors",
"     </li>",
"     <li>",
"      Histamine type 2 receptor antagonists",
"     </li>",
"     <li>",
"      Antacids",
"     </li>",
"     <li>",
"      Prokinetics",
"     </li>",
"     <li>",
"      Surface agents",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Proton pump inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proton pump inhibitors (PPI) block acid secretion by irreversibly binding to and inhibiting the hydrogen-potassium ATPase pump that resides on the luminal surface of the parietal cell membrane. The drugs in this class include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/23/24952?source=see_link\">",
"     omeprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/53/2904?source=see_link\">",
"     lansoprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/44/43718?source=see_link\">",
"     rabeprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/45/22231?source=see_link\">",
"     pantoprazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/38/21095?source=see_link\">",
"     esomeprazole",
"    </a>",
"    . The pharmacology and efficacy of PPIs are discussed in detail separately. The differences in pharmacology and efficacy among drugs in this class appear to be small and of uncertain clinical significance, thus it is reasonable to make treatment decisions based on cost and on which dosing formulation is accepted by the child. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25034?source=see_link\">",
"     \"Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/23/24952?source=see_link\">",
"     Omeprazole",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/53/2904?source=see_link\">",
"     lansoprazole",
"    </a>",
"    have been most extensively studied in children and are approved by the US Food and Drug Administration (FDA) for this age group, but not in infants [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/1\">",
"     1",
"    </a>",
"    ]. Approval updates and labeling changes are available on the FDA website [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proton pump inhibitors (PPIs) are superior to histamine type 2 receptor antagonists (H2RAs) in relieving symptoms and healing esophagitis in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. They produce a greater reduction in acid secretion, have a longer duration of action, and tolerance does not develop. There are no similar randomized trials in children, but several case series report that PPIs have healed severe esophagitis that had been unresponsive to H2RAs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In infants with irritability or regurgitation, several randomized, placebo-controlled trials and a systematic review conclude that PPIs are no more effective than placebo in improving symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. These studies do not address the efficacy of PPIs or other acid-suppressing regimens in infants with marked histologic evidence of esophagitis on endoscopic biopsies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30441?source=see_link&amp;anchor=H25#H25\">",
"     \"Gastroesophageal reflux in infants\", section on 'Pharmacotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children and adolescents with esophagitis or marked GERD symptoms, the only controlled trials compare PPIs with alternate forms of acid suppression. PPIs have not been superior for symptom relief or histologic healing, as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial compared the efficacy of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/23/24952?source=see_link\">",
"       omeprazole",
"      </a>",
"      (40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      surface area) with high-dose",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/1/33815?source=see_link\">",
"       ranitidine",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/kg/day)",
"      </span>",
"      in 32 children (age 6 months to 13.4 years) with severe esophagitis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/11\">",
"       11",
"      </a>",
"      ]. Both regimens were associated with significant improvement in symptoms and in endoscopic and histologic findings and were effective in reducing esophageal acid exposure during 24-hour pH monitoring. Thus, in this small short-term trial, omeprazole offered no advantage over high-dose ranitidine.",
"     </li>",
"     <li>",
"      A randomized trial compared the efficacy of two doses of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/38/21095?source=see_link\">",
"       esomeprazole",
"      </a>",
"      (20 mg versus 40 mg once daily) in 148 adolescents with symptoms of GERD, including heartburn, epigastric pain, or vomiting [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/12\">",
"       12",
"      </a>",
"      ]. There were marked improvements in GERD symptoms for both treatment groups as compared to baseline, with a trend toward greater symptom improvement in the group treated with 40 mg esomeprazole, although this difference was not statistically significant.",
"     </li>",
"     <li>",
"      A randomized trial compared the efficacy of low-dose",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/23/24952?source=see_link\">",
"       omeprazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/1/33815?source=see_link\">",
"       ranitidine",
"      </a>",
"      , and placebo in maintaining remission of esophagitis which had been healed by high-dose PPI treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/13\">",
"       13",
"      </a>",
"      ]. Each of these treatments was highly effective in maintaining remission as measured by symptoms and histopathology.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, available studies in children provide only indirect evidence of PPI efficacy because they are only shown to be equivalent to alternate acid-suppressing regimens for symptom relief and histologic healing, although PPIs are more effective in reducing gastric acidity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/9\">",
"     9",
"    </a>",
"    ]. Our suggestion that PPIs be selected in preference to other forms of acid suppression in patients with documented esophagitis is based on this indirect evidence and extrapolation from studies in adults, as well as observations that H2 RA are more likely to be associated with tachyphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/1,14\">",
"     1,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of PPIs on extraesophageal manifestations of GERD in children such as asthma has not been well studied, although they are already being used for this purpose in children based upon data in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39816?source=see_link\">",
"     \"Gastroesophageal reflux and asthma\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H26\">",
"     'Asthma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dosing guidelines for PPIs vary considerably; infants and younger children appear to metabolize some PPIs more rapidly and may require higher per-kilogram dosing than older individuals (",
"    <a class=\"graphic graphic_table graphicRef55435 \" href=\"UTD.htm?12/0/12302\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/1,15,16\">",
"     1,15,16",
"    </a>",
"    ]. In some pediatric studies, effective doses of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/23/24952?source=see_link\">",
"     omeprazole",
"    </a>",
"    ranged from 0.3 to 3.5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    (maximum 80",
"    <span class=\"nowrap\">",
"     mg/day);",
"    </span>",
"    doses of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/53/2904?source=see_link\">",
"     lansoprazole",
"    </a>",
"    were 0.73 to 1.66",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    (maximum 30",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some children may require twice daily dosing to achieve optimal acid suppression; we suggest starting with once daily dosing advancing to twice daily dosing if there is clear symptom improvement with the increased frequency. Some providers alternate doses of a PPI with a histamine type 2 receptor antagonist, but there is no specific evidence supporting this practice. The duration of therapy depends on the type and severity of peptic disease for which it is used. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Several of these drugs are formulated as capsules containing enteric-coated granules that can be sprinkled onto soft foods for administration to young children.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/53/2904?source=see_link\">",
"     Lansoprazole",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/23/24952?source=see_link\">",
"     omeprazole",
"    </a>",
"    are also available as flavored powders for preparing a suspension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;One concern that limits the use of PPIs is the phenomenon of acid rebound, in which acid output increases after withdrawal to levels higher than the baseline level. The evidence for acid rebound is from studies in adults, and is described in detail in a separate topic review. Optimal management has not been established. When attempting to discontinue PPIs in patients who have been treated chronically, we and others generally taper PPIs gradually to minimize the potential problem of acid rebound [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/1\">",
"     1",
"    </a>",
"    ], but a study of a tapering regimen in adults failed to establish a clinical benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25034?source=see_link&amp;anchor=H27968048#H27968048\">",
"     \"Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders\", section on 'Discontinuing proton pump inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential safety concerns about chronic use of PPIs include an increased susceptibility to enteric infections, particularly Clostridium difficile. In 2012, the Food and Drug issued a",
"    <a class=\"external\" href=\"file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm290838.htm?source=govdelivery\">",
"     Safety Alert",
"    </a>",
"    about this issue, encouraging providers to consider the possibility of C. difficile associated diarrhea in PPI users with persistent diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/19\">",
"     19",
"    </a>",
"    ]. Other safety concerns about PPIs include community-acquired pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], vitamin B12 malabsorption and nephritis (reported in older adults), and hypomagnesemia due to reduced intestinal absorption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16745?source=see_link&amp;anchor=H15#H15\">",
"     \"Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology\", section on 'Other risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute interstitial nephritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25034?source=see_link&amp;anchor=H59974871#H59974871\">",
"     \"Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders\", section on 'Safety'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Most data on the long-term safety of PPIs is from studies in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/22\">",
"     22",
"    </a>",
"    ]. The only long-term data in children are from an observational study of 166 patients, in whom the median treatment duration was three years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/23\">",
"     23",
"    </a>",
"    ]. Most of the subjects had conditions predisposing to GERD (eg, neuromotor disorders), and the drugs were generally well tolerated. The long-term consequences of PPI-induced hypergastrinemia are unknown. In one study of children undergoing long-term treatment with PPIs (median length of treatment 2.8 years), mild enterochromaffin cell-like hyperplasia was noted in almost half of children, but none developed atrophic gastritis or carcinoid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/24\">",
"     24",
"    </a>",
"    ]. Concerns about long-term effects on bone metabolism have been raised but not established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=see_link&amp;anchor=H16#H16\">",
"     \"Drugs that affect bone metabolism\", section on 'Proton pump inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Histamine type 2 receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histamine type 2 receptor antagonists (H2RAs) have moderate effects on gastroesophageal reflux, as measured by relief of symptoms and mucosal healing. However, they are somewhat less effective than the proton pump inhibitor class [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The H2RAs inhibit acid secretion by blocking histamine H2 receptors on the parietal cell. Four H2RAs are used in the United States:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/58/43943?source=see_link\">",
"       Cimetidine",
"      </a>",
"      (Tagamet&reg;)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/1/33815?source=see_link\">",
"       Ranitidine",
"      </a>",
"      (Zantac&reg;)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/61/29655?source=see_link\">",
"       Famotidine",
"      </a>",
"      (Pepcid&reg;)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38885?source=see_link\">",
"       Nizatidine",
"      </a>",
"      (Axid&reg;)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Over-the-counter preparations containing doses less-than-prescription strength are available for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/58/43943?source=see_link\">",
"     cimetidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/1/33815?source=see_link\">",
"     ranitidine",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/61/29655?source=see_link\">",
"     famotidine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Multiple controlled trials in adults have evaluated the efficacy of H2RAs in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/4\">",
"     4",
"    </a>",
"    ]. These studies have shown that H2RAs are superior to placebo for healing esophagitis and improving symptoms. However, their benefit is greatest for patients with mild esophagitis, and tolerance (tachyphylaxis) eventually develops, limiting efficacy for long-term management [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link&amp;anchor=H8#H8\">",
"     \"Medical management of gastroesophageal reflux disease in adults\", section on 'Maintenance therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fewer studies have been performed in children, but the results are similar to the experience in adults. The following summaries describe two of the few controlled trials that have been published:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study included 32 children (21 to 29 months) with esophagitis who were randomly assigned to receive",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/58/43943?source=see_link\">",
"       cimetidine",
"      </a>",
"      (30 to 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/25\">",
"       25",
"      </a>",
"      ]. After 12 weeks, healing was observed significantly more often in the cimetidine-treated group. Improvement of esophagitis was seen in all patients with mild or moderate esophagitis compared to only 57 percent of patients with severe esophagitis.",
"     </li>",
"     <li>",
"      Another trial included 26 children with endoscopically proven mild to moderate esophagitis who were randomly assigned to receive",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38885?source=see_link\">",
"       nizatidine",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in two doses) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/26\">",
"       26",
"      </a>",
"      ]. At the end of eight weeks, healing was observed significantly more often in children who received nizatidine (69 versus 15 percent), a response that also was reflected in decreased acid exposure as assessed by esophageal pH monitoring.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of histamine type 2 receptor antagonists is associated with an increased risk of enteric infection, particularly C. difficile, and community-acquired pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16745?source=see_link&amp;anchor=H15#H15\">",
"     \"Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology\", section on 'Other risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antacids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antacids are commonly used for short-term relief of symptoms of GER in infants and children. Neither efficacy nor safety has been well studied, and chronic use is generally not recommended.",
"   </p>",
"   <p>",
"    Antacids work by neutralizing gastric pH and thereby decreasing the exposure of the esophageal mucosa to gastric acidity during episodes of reflux. Various preparations that are commercially available usually contain the combination of magnesium and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/36/21062?source=see_link\">",
"     aluminum hydroxide",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/38/18024?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    . At least two studies suggested that high-dose antacid therapy with",
"    <span class=\"nowrap\">",
"     magnesium/aluminum-containing",
"    </span>",
"    acids was as effective as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/58/43943?source=see_link\">",
"     cimetidine",
"    </a>",
"    for the short-term treatment of esophagitis in children [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. However, treatment with aluminum-containing antacids can significantly increase plasma aluminum levels in infants to levels that have been associated with complications such as osteopenia, microcytic anemia, and neurotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. As a result, their use generally is restricted to short-term relief of symptoms in older children and adolescents. The efficacy and safety of other types of antacids in children have not been well studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prokinetic drugs enhance esophageal peristalsis and accelerate gastric emptying, providing a rationale for their use in GERD. However, the agents that have some established efficacy also have significant safety concerns [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, they should be considered for use only in carefully selected patients, including those who have failed antisecretory therapy (PPIs or H2RAs). In addition, prokinetic agents may be considered for patients who are healthy (no evidence or acid reflux or other disease on evaluation) for whom quality of life is adversely affected by recurrent vomiting or regurgitation.",
"   </p>",
"   <p>",
"    Careful monitoring for drug interactions and other safety concerns is necessary if these drugs are chosen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link&amp;anchor=H6#H6\">",
"     \"Medical management of gastroesophageal reflux disease in adults\", section on 'Adjunctive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cisapride &ndash; Cisapride is a serotonergic agent that facilitates the release of acetylcholine within the myenteric plexus. Although cisapride has generally had a good safety profile, it also has been associated with rare but potentially life-threatening cardiac arrhythmias [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/32\">",
"       32",
"      </a>",
"      ]. As result, its availability has been severely restricted in the United States and Europe. Prescriptions for the drug can only be filled directly through the manufacturer after providing documentation as to the need for the drug and assessment of risk factors for cardiac arrhythmias in the individual patient. The drug has been removed from the market entirely in some countries but remains freely available in others. Thus, although cisapride continues to be used in children in some countries, it currently has little role in the management of GERD in the United States and Europe.",
"      <br/>",
"      <br/>",
"      Cardiac toxicity is most likely to occur when cisapride is taken in combination with macrolide antibiotics (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"       erythromycin",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"       clarithromycin",
"      </a>",
"      ) or drugs in the imidazole class (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/10/34976?source=see_link\">",
"       ketoconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"       fluconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/59/6074?source=see_link\">",
"       itraconazole",
"      </a>",
"      , or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"       metronidazole",
"      </a>",
"      ) and HIV protease inhibitors, which inhibit the cytochrome P-4503A4 enzyme and increase cisapride levels.",
"      <br/>",
"      <br/>",
"      The efficacy of cisapride in children with GERD has been studied in controlled trials, at least six of which focused on infants younger than 2 years old [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/33-39\">",
"       33-39",
"      </a>",
"      ]. A systematic review evaluating nine trials of cisapride treatment for GERD in children concluded that although cisapride reduces esophageal acid exposure, as measured by the reflux index, there was no clear evidence that cisapride reduces the symptoms of GERD [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/40\">",
"       40",
"      </a>",
"      ]. The authors found statistical evidence of publication bias in the literature, accounting for the preponderance of studies showing a positive effect on GERD.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/47/759?source=see_link\">",
"       Metoclopramide",
"      </a>",
"      &ndash; Because of the uncertain efficacy and the frequent side effects, metoclopramide is indicated infrequently in the treatment of GERD in children.",
"      <br/>",
"      <br/>",
"      Metoclopramide causes central and peripheral dopamine D2 antagonism, stimulates cholinergic receptors on gastric smooth muscle cells, and enhances acetylcholine release at the neuromuscular junction.",
"      <br/>",
"      <br/>",
"      At least five controlled trials in children with GERD have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/41-45\">",
"       41-45",
"      </a>",
"      ]. Two of the trials demonstrated a benefit on the frequency and volume of vomiting [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/41,44\">",
"       41,44",
"      </a>",
"      ], whereas in three other studies the benefit was similar to that of placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/42,43,45\">",
"       42,43,45",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A meta-analysis of seven trials evaluating metoclopramide for GERD in children younger than 2 years of age, including four controlled trials [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/41-43\">",
"       41-43",
"      </a>",
"      ], found some benefit in comparison to placebo, but at the expense of increased side effects [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/46\">",
"       46",
"      </a>",
"      ]. However, a systematic review of 12 case-control, cohort, and randomized studies, including three of the controlled trials described above [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/41-43\">",
"       41-43",
"      </a>",
"      ], reached a different conclusion [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/47\">",
"       47",
"      </a>",
"      ]. The authors found marked heterogeneity in the patient populations, dosing, and outcomes studied; they did not perform a meta-analysis and concluded that the available evidence is insufficient to support or oppose the use of metoclopramide [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/47\">",
"       47",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Because metoclopramide crosses the blood-brain barrier, there may be central nervous system side effects including sedation (very common and dose-related), extrapyramidal reaction (moderately common but reversible), and tardive dyskinesia (which is very rare but may be irreversible) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/1\">",
"       1",
"      </a>",
"      ]. Gynecomastia and galactorrhea have also been reported.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7878?source=see_link\">",
"       Baclofen",
"      </a>",
"      &ndash; Baclofen is a gamma-amino-butyric acid B (GABA-B) receptor agonist that inhibits the transient relaxations of the lower esophageal sphincter that are a predominant mechanism of reflux. In adults, baclofen reduces reflux symptoms after acute or chronic dosing [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/48\">",
"       48",
"      </a>",
"      ]. In children, baclofen also reduced the frequency of esophageal sphincter relaxation and esophageal acid exposure, and accelerated gastric emptying [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]. Although these findings are encouraging, further study is required before baclofen can be generally recommended to pediatric patients with GERD [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/1\">",
"       1",
"      </a>",
"      ]. Potential side effects include dyspepsia, drowsiness, and lowered seizure threshold.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1717?source=see_link\">",
"       Domperidone",
"      </a>",
"      &ndash; Results of trials examining the efficacy of domperidone have been ambiguous. Although it may have fewer central nervous system side effects than",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/47/759?source=see_link\">",
"       metoclopramide",
"      </a>",
"      , its safety has not been carefully examined, and it is currently not available in the United States.",
"      <br/>",
"      <br/>",
"      Domperidone (Motilium&reg;) is a D2-blocker with selective peripheral activity in the upper gastrointestinal tract. Neurologic side effects have been reported, but are probably less frequent than those reported for metoclopramide. However, domperidone reversibly prolongs ventricular repolarization, manifested as a prolonged QTc interval on the electrocardiogram [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]. This could cause cardiac arrhythmias (torsades de pointes), particularly if domperidone is administered intravenously, or if there is moderate hyperkalemia or concomitant administration of other drugs that prolong the QTc interval.",
"      <br/>",
"      <br/>",
"      Experience with domperidone in the treatment of GERD in children is limited. Two controlled trials that included a total of 107 infants concluded that domperidone drops or suppositories were more effective than was placebo or metoclopramide in controlling nausea, vomiting, and regurgitation [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/44,53\">",
"       44,53",
"      </a>",
"      ]. In contrast, two other studies found no improvement in any of these measures after four and eight weeks of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/54,55\">",
"       54,55",
"      </a>",
"      ]. A systematic review failed to find robust evidence for efficacy of domperidone in reducing reflux symptoms in children [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/58/16291?source=see_link\">",
"       Bethanechol",
"      </a>",
"      &ndash; There is minimal evidence supporting the use of bethanechol for treatment of gastroesophageal reflux in children or adults. The only clinical trials are old and they use outcomes of questionable clinical importance.",
"      <br/>",
"      <br/>",
"      Bethanechol is a direct cholinergic agonist and acutely increases the contraction of the lower esophageal sphincter. However, there is little evidence that this causes clinical improvement in gastroesophageal reflux.",
"      <br/>",
"      <br/>",
"      One crossover trial involving 30 infants suggested that active treatment was associated with a decrease in the frequency of vomiting [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/57\">",
"       57",
"      </a>",
"      ]. A study comparing bethanechol to antacids found no significant difference in clinical outcomes or esophageal acid exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Surface agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surface agents work by creating a barrier that impedes peptic injury to mucosal surfaces. Only two such substances have been evaluated in the treatment of GERD: sodium alginate and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/4/8261?source=see_link\">",
"     sucralfate",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Sodium alginate (derived from seaweed) forms a surface gel that creates a physical barrier against regurgitation of gastric contents and protects the esophageal mucosa. Studies comparing its efficacy on symptoms and esophageal acid exposure with other available treatments have produced conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/59-62\">",
"     59-62",
"    </a>",
"    ]. It currently is used infrequently in the treatment of children with GERD. A preparation available in the United States (Gaviscon) also contains an antacid and is used for the temporary relief of heartburn in adults.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/4/8261?source=see_link\">",
"     Sucralfate",
"    </a>",
"    (aluminum sucrose sulfate) adheres to the mucosal surface, promoting healing and protecting from further peptic injury by mechanisms that are incompletely understood. A study in adults with nonerosive esophagitis found that it decreased symptoms and promoted healing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/63\">",
"     63",
"    </a>",
"    ]. One controlled trial in children suggested that it was as effective as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/58/43943?source=see_link\">",
"     cimetidine",
"    </a>",
"    for treatment of esophagitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/64\">",
"     64",
"    </a>",
"    ]. However, because of concerns related to aluminum toxicity and the availability of other treatments, sucralfate has a minimal, if any, role in the treatment of GERD in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antireflux surgery appears to be successful in controlling reflux in many patients with debilitating gastroesophageal reflux disease (GERD) that is refractory to medical management, but the outcome of the intervention has not been systematically studied. Surgery is most often considered for patients with pulmonary disease that is clearly due to aspiration from refluxed material, and occasionally for patients with failure to thrive that does not respond to tube feedings, or intractable esophagitis or emesis that does not respond to proton pump inhibitors. Many of the children who have undergone antireflux surgery have underlying neurological impairment such as cerebral palsy.",
"   </p>",
"   <p>",
"    The efficacy of surgery has been supported only by the results of numerous case series that used different inclusion criteria, focused predominantly on neurologically impaired children, had short follow-up periods, and reported variable endpoints [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/65-72\">",
"     65-72",
"    </a>",
"    ]. These limitations and the absence of controlled trials represent potentially critical issues in defining the role of surgery in the management of GERD in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly performed operation is a Nissen fundoplication. This procedure originally involved passage of the gastric fundus behind the esophagus to encircle up to 6 cm of the distal esophagus. However, many variations and modifications have been described, and a Nissen fundoplication may be performed differently by different surgeons. Variables include approach (transthoracic or abdominal), portion of stomach wall used (anterior and posterior or anterior only), combination with other procedures (eg, vagotomy or gastroplasty), the looseness of the wrap, the completeness of the wrap, and the length of the wrap.",
"   </p>",
"   <p>",
"    The Nissen fundoplication is now performed laparoscopically at many centers. The laparoscopic technique appears to have fewer acute complications but a somewhat higher reoperation rate than open fundoplication, at least in centers with extensive experience in the technique [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/65,73-75\">",
"     65,73-75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most surgeons choose to perform a loose (\"floppy\") Nissen fundic wrap that is approximately 1 to 2 cm in length, including a posterior crural repair. A common modification is a 360&ordm; fundic wrap without ligation of the short gastric vessels (Rosetti-Nissen). A partial 270&ordm; wrap (Toupet) is used for patients with severe associated motor abnormalities (",
"    <a class=\"graphic graphic_figure graphicRef51049 \" href=\"UTD.htm?0/62/995\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/67,70\">",
"     67,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following general conclusions regarding surgery for GERD in children can be derived from the multitude of case series:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptom improvement has been described in approximately 60 to 90 percent of children [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/1\">",
"     1",
"    </a>",
"    ], but \"failure rates\" (variously defined) vary widely among reports, ranging from 2 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/74\">",
"     74",
"    </a>",
"    ]. As an example, in one study, nearly two-thirds of children had ongoing reflux, requiring treatment two months following fundoplication [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/71\">",
"     71",
"    </a>",
"    ]. In studies that have reported longer-term outcomes, most demonstrate higher rates of failure within one to three years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/76\">",
"     76",
"    </a>",
"    ]. Several studies suggest higher failure rates in children with neurological impairment, chronic respiratory conditions, repaired esophageal atresia, and in infants [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/1,72,74,77\">",
"     1,72,74,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experience in adults has demonstrated that patients who do not respond to adequate doses of medical therapy (particularly those with typical features of GERD such as heartburn) also may have a poor response to surgery, questioning the role of antireflux surgery in patients with symptoms refractory to medical therapy. Furthermore, long-term follow-up of patients who underwent standard antireflux surgery reveals that many continue to depend upon medical therapy to control symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42905?source=see_link\">",
"     \"Surgical management of gastroesophageal reflux in adults\"",
"    </a>",
"    .) Similar unsatisfactory outcomes were seen in a report of children with cystic fibrosis and GERD [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/78\">",
"     78",
"    </a>",
"    ]. Nearly half of the children had ongoing symptoms of GERD after fundoplication, and overall there was little benefit to pulmonary function. Twelve percent of patients had complications that required a subsequent surgical procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of antireflux surgery range from 2 to 45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/1,79,80\">",
"     1,79,80",
"    </a>",
"    ]. The most common complications included breakdown of the wrap (1 to 13 percent), small bowel obstruction (1 to 11 percent), gas bloat syndrome (2 to 8 percent), infection (1 to 9 percent), atelectasis or pneumonia (4 to 13 percent), perforation (2 to 4 percent), persistent esophageal stricture (1 to 9 percent), and esophageal obstruction (1 to 9 percent). Complications that occurred less frequently included dumping syndrome, an incisional hernia, and gastroparesis. Reoperation was required in 3 to 19 percent of patients, and operative mortality ranged from 0 to 5 percent.",
"   </p>",
"   <p>",
"    Patients with neurological impairment or those requiring a second antireflux operation appear to have somewhat higher frequency of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/1,76\">",
"     1,76",
"    </a>",
"    ]. However, children without underlying disorders also may have poor outcomes. Retching (dry heaves) is common in children who have undergone fundoplication, particularly children who are neurologically impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/74,81\">",
"     74,81",
"    </a>",
"    ]. Treatment for this complication is difficult, and if the retching is not controlled it may disrupt the surgical repair. Anticholinergic drugs and histamine type 1 receptor antagonists may be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/82\">",
"     82",
"    </a>",
"    ]. Symptoms tend to improve after several months.",
"   </p>",
"   <p>",
"    In aggregate, these data suggest that surgery is often associated with favorable outcomes, although potential risks should be considered. However, the benefit of surgery versus medical therapy in subsets of infants and children with specific symptoms has not been adequately studied. Causes of symptoms other than GERD should be rigorously excluded before considering anti-reflux surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pre-surgical evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic tests that may be used to help determine whether anti-reflux surgery is appropriate depend on the patient's clinical presentation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with chronic esophagitis unresponsive to acid suppression might be considered for anti-reflux surgery. However, they should first undergo an upper endoscopy with biopsies and prolonged esophageal pH monitoring to exclude other causes of esophageal inflammation such as eosinophilic esophagitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link\">",
"       \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with predominantly respiratory symptoms should undergo thorough evaluation to document association of GERD with respiratory symptoms. This evaluation may include review of all radiographic studies, bronchoalveolar lavage, esophageal pH monitoring, polysomnography, and swallowing studies. However, because even normal degrees of reflux may have adverse effects in some children, surgery may be beneficial for some children with respiratory symptoms even if the esophageal pH study is normal [",
"      <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If aspiration is suspected in a child with neurologic impairment, fundoplication should be approached with caution: although the fundoplication can reduce gastroesophageal reflux, it can also impede esophageal clearance and increase the likelihood of aspiration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EXTRAESOPHAGEAL MANIFESTATIONS OF GERD",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Asthma with GER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroesophageal reflux (GER) is an established trigger for asthma in many patients. In about 60 percent of children with asthma and clinical or laboratory evidence of GER, asthma control will improve with aggressive treatment for reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/1,84\">",
"     1,84",
"    </a>",
"    ]. However, it is difficult to predict responders [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/85\">",
"     85",
"    </a>",
"    ]. Therefore, we suggest a trial of vigorous acid suppression for patients with persistent asthma and clear symptoms suggesting gastroesophageal reflux disease (GERD), including frequent heartburn or regurgitation. Treatment trials of three months are often used in adults; management after three months depends upon the response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39816?source=see_link&amp;anchor=H12#H12\">",
"     \"Gastroesophageal reflux and asthma\", section on 'Empiric therapy in patients with symptomatic GERD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The utility of treating for GERD in selected patients with asthma has been better studied in adults, using randomized controlled trials. This evidence and recommendations are similar to those in children, and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39816?source=see_link&amp;anchor=H7#H7\">",
"     \"Gastroesophageal reflux and asthma\", section on 'Evidence that GERD treatment improves asthma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In many patients with asthma, GERD may be silent and diagnosed only with esophageal pH monitoring. Thus, pH monitoring or an empiric trial of antireflux treatment should be considered in patients with severe symptoms of asthma, and particularly nocturnal-onset asthma, even in the absence of apparent symptoms of GERD. Other causes of wheezing should be carefully excluded, including foreign body aspiration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\", section on 'Asthma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/41/1689?source=see_link\">",
"     \"Wheezing illnesses other than asthma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is inadequate evidence to determine the role of anti-reflux surgery for patients with asthma and GERD. Case series in adults and children generally report improvement in respiratory symptoms after fundoplication for selected patients with severe asthma, in whom a relationship to GERD is well established and there has been a clear response to acid suppressing medication [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/1,86-88\">",
"     1,86-88",
"    </a>",
"    ]. Clinical findings predicting response to surgery include a clear history of reflux symptoms preceding the onset of asthma, a history of recurrent pneumonia, lack of atopic symptoms or seasonal variation, and nocturnal episodes of asthma. However, these results should be interpreted with caution because of variations in selection criteria and lack of randomization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42905?source=see_link\">",
"     \"Surgical management of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Recurrent pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no definitive tests to determine whether GERD is causing recurrent pneumonia in a given patient. Clinical decisions must be based on an individual patient's clinical risk and a combination of tests for reflux and aspiration. The possibility of aspiration during swallowing should be fully investigated, because this is a more common cause of recurrent pneumonia than GERD. If the pneumonia is consistently in the same area, an H-type tracheo-esophageal fistula should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link&amp;anchor=H22#H22\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\", section on 'Recurrent pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When aspiration and recurrent pneumonia are strongly suspected to be related to GERD, aggressive treatment is appropriate to prevent chronic progression of pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. If pulmonary disease is mild, medical treatment with acid suppression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prokinetic agents can be used, as long as pulmonary function can be monitored carefully in follow-up. If pulmonary disease is severe or progressive, surgical treatment with fundoplication should be considered. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Surgery'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/11/40114?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux disease) in children and adolescents (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/50/32547?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux disease) in children and adolescents (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16643?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding discussion underscores the limited data available from well-designed controlled trials to guide optimal strategies for the management of gastroesophageal reflux disease (GERD) in children. However, in children with distinct symptoms of heartburn or documented esophagitis, the evidence base for treatment recommendations is analogous to and strengthened by observations in adults. The following recommendations are based upon a review of the available evidence by a committee of experts [",
"    <a class=\"abstract\" href=\"UTD.htm?19/33/19994/abstract/1\">",
"     1",
"    </a>",
"    ] and from clinical experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Treatment options",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lifestyle changes, including avoidance of specific foods and positional changes, confer modest improvement in some reflux-related symptoms in adults. However, they have not been carefully evaluated in children and may be difficult to implement. Thus, they should not be used as the sole intervention for children with clinically significant gastroesophageal reflux disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Lifestyle changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acid-suppressing medications are reasonably safe and effective for the treatment of established acid-related gastroesophageal reflux disease. Proton pump inhibitor (PPI) medications are the most effective for short- or long-term acid suppression, are valuable for the treatment of reflux esophagitis and often for asthmatic symptoms caused by reflux. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Proton pump inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment with prokinetic agents improves gastric emptying",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the action of the lower esophageal sphincter, and could thus decrease both acidic and non-acidic gastric gastroesophageal reflux. However, the prokinetic agents that are currently available either have limited efficacy or significant safety concerns. Thus, we recommend NOT using prokinetic agents for the routine treatment of children with gastroesophageal reflux disease (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). These drugs can be considered in patients who have failed antisecretory therapy, with careful monitoring for drug interactions and other adverse effects. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prokinetics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Heartburn",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children or adolescents with heartburn, we suggest a trial of treatment with the lifestyle changes described above (weight loss and smoking cessation; head of bed elevation; and avoidance of chocolate, caffeine, spicy foods, alcohol, and other foods that exacerbate symptoms) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Lifestyle changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the symptoms are moderate or severe, or fail to respond to lifestyle changes, we recommend a trial of acid suppression therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Either a histamine type 2 receptor antagonist or proton pump inhibitor is a reasonable first choice, and a typical trial duration is two to four weeks. However, for patients who do not improve on a histamine type 2 receptor blocker, we recommend treatment with a PPI (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Persistent or recurrent symptoms on a PPI should prompt referral for an upper endoscopy with biopsy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Lifestyle changes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Pharmacotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Esophagitis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children with endoscopically documented reflux-related esophagitis, we recommend treatment with an acid-suppressing medication (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We also suggest a concurrent trial of lifestyle changes (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For initial treatment, we suggest a proton-pump inhibitor (PPI) rather than a histamine type 2 receptor antagonist (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Infants and younger children appear to metabolize PPIs more rapidly and may require higher per-kilogram dosing than older individuals (",
"      <a class=\"graphic graphic_table graphicRef55435 \" href=\"UTD.htm?12/0/12302\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Proton pump inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Further evaluation and treatment depends on the severity of the esophagitis at baseline and on the degree of symptom relief. Patients with only mild esophagitis can be treated for four to eight weeks, and reassessed based upon the degree of symptom relief. Those with erosive esophagitis should undergo a repeat endoscopy after three to six months of treatment to demonstrate healing. If healing or symptom relief is incomplete, medical therapy should be optimized. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pharmacotherapy'",
"      </a>",
"      above.) Surgery is a consideration for refractory cases. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term treatment with acid suppressing medications is appropriate if symptoms or endoscopy indicate chronic or recurrent esophagitis. Because tolerance develops to histamine type 2 receptor antagonists, these are not ideal choices for continuous maintenance therapy, but might be useful in an intermittent treatment regimen for milder disease. When continuous therapy is necessary, we suggest treatment with a proton pump inhibitor (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Dysphagia or odynophagia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysphagia may be caused by GERD, but also may have other causes, such as eosinophilic esophagitis, pill esophagitis, esophageal dysmotility, or foreign body. Children or adolescents with odynophagia also should be evaluated for esophagitis caused by cytomegalovirus, herpes, or Candida. Children with these symptoms should be carefully evaluated for other causes. Empiric treatment for reflux is not recommended unless other causes of the symptoms have been excluded. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In about 60 percent of children with asthma and clinical or laboratory evidence of GER, asthma control will improve with aggressive treatment for reflux, but it is difficult to predict responders. Therefore, we suggest a three-month trial of a PPI for patients with persistent asthma and frequent heartburn or regurgitation suggesting GERD (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Asthma with GER'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Carlos Lifschitz, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/1\">",
"      Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2009; 49:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/2\">",
"      Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006; 166:965.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration: Drugs@FDA Web site www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (Accessed on May 23, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/4\">",
"      Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/5\">",
"      Hassall E. Decisions in diagnosing and managing chronic gastroesophageal reflux disease in children. J Pediatr 2005; 146:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/6\">",
"      Hassall E, Israel D, Shepherd R, et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. J Pediatr 2000; 137:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/7\">",
"      Moore DJ, Tao BS, Lines DR, et al. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr 2003; 143:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/8\">",
"      Orenstein SR, Hassall E, Furmaga-Jablonska W, et al. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr 2009; 154:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/9\">",
"      van der Pol RJ, Smits MJ, van Wijk MP, et al. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. Pediatrics 2011; 127:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/10\">",
"      Winter H, Kum-Nji P, Mahomedy SH, et al. Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1-11 months old with symptomatic GERD. J Pediatr Gastroenterol Nutr 2010; 50:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/11\">",
"      Cucchiara S, Minella R, Iervolino C, et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Arch Dis Child 1993; 69:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/12\">",
"      Gold BD, Gunasekaran T, Tolia V, et al. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2007; 45:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/13\">",
"      Boccia G, Manguso F, Miele E, et al. Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable? Am J Gastroenterol 2007; 102:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/14\">",
"      Hyman PE, Garvey TQ 3rd, Abrams CE. Tolerance to intravenous ranitidine. J Pediatr 1987; 110:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/15\">",
"      Litalien C, Th&eacute;or&ecirc;t Y, Faure C. Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet 2005; 44:441.",
"     </a>",
"    </li>",
"    <li>",
"     Phillips JO, Parsons DS, Fitts SW. Flavored lansoprazole suspension in pediatric GERD. World congress of Pediatric Gastroenterology, Hepatology, and Nutrition 2000. Abstract 750966.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/17\">",
"      Gibbons TE, Gold BD. The use of proton pump inhibitors in children: a comprehensive review. Paediatr Drugs 2003; 5:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/18\">",
"      Bj&ouml;rnsson E, Abrahamsson H, Simr&eacute;n M, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006; 24:945.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). Available at: file://www.fda.gov/Drugs/DrugSafety/ucm290510.htm (Accessed on February 08, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/20\">",
"      Canani RB, Cirillo P, Roggero P, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006; 117:e817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/21\">",
"      Rosh JR, Hassall E. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. J Pediatr Gastroenterol Nutr 2006; 43:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/22\">",
"      Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/23\">",
"      Hassall E, Kerr W, El-Serag HB. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr 2007; 150:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/24\">",
"      Hassall E, Owen D, Kerr W, et al. Gastric histology in children treated with proton pump inhibitors (PPIs) long-term. Gastroenterology 2008; 134:A174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/25\">",
"      Cucchiara S, Gobio-Casali L, Balli F, et al. Cimetidine treatment of reflux esophagitis in children: an Italian multicentric study. J Pediatr Gastroenterol Nutr 1989; 8:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/26\">",
"      Simeone D, Caria MC, Miele E, Staiano A. Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. J Pediatr Gastroenterol Nutr 1997; 25:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/27\">",
"      Cucchiara S, Staiano A, Romaniello G, et al. Antacids and cimetidine treatment for gastro-oesophageal reflux and peptic oesophagitis. Arch Dis Child 1984; 59:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/28\">",
"      Iacono G, Carroccio A, Montalto G, et al. [Magnesium hydroxide and aluminum hydroxide in the treatment of gastroesophageal reflux]. Minerva Pediatr 1991; 43:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/29\">",
"      Tsou VM, Young RM, Hart MH, Vanderhoof JA. Elevated plasma aluminum levels in normal infants receiving antacids containing aluminum. Pediatrics 1991; 87:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/30\">",
"      Woodard-Knight L, Fudge A, Teubner J, Simmer K. Aluminium absorption and antacid therapy in infancy. J Paediatr Child Health 1992; 28:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/31\">",
"      Sedman A. Aluminum toxicity in childhood. Pediatr Nephrol 1992; 6:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/32\">",
"      Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996; 335:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/33\">",
"      Cucchiara S, Staiano A, Boccieri A, et al. Effects of cisapride on parameters of oesophageal motility and on the prolonged intraoesophageal pH test in infants with gastro-oesophageal reflux disease. Gut 1990; 31:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/34\">",
"      Vandenplas Y, de Roy C, Sacre L. Cisapride decreases prolonged episodes of reflux in infants. J Pediatr Gastroenterol Nutr 1991; 12:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/35\">",
"      Saye ZN, Forget PP, Geubelle F. Effect of cisapride on gastroesophageal reflux in children with chronic bronchopulmonary disease: a double-blind cross-over pH-monitoring study. Pediatr Pulmonol 1987; 3:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/36\">",
"      Scott RB, Ferreira C, Smith L, et al. Cisapride in pediatric gastroesophageal reflux. J Pediatr Gastroenterol Nutr 1997; 25:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/37\">",
"      Cohen RC, O'Loughlin EV, Davidson GP, et al. Cisapride in the control of symptoms in infants with gastroesophageal reflux: A randomized, double-blind, placebo-controlled trial. J Pediatr 1999; 134:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/38\">",
"      Van Eygen M, Van Ravensteyn H. Effect of cisapride on excessive regurgitation in infants. Clin Ther 1989; 11:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/39\">",
"      Cucchiara S, Staiano A, Capozzi C, et al. Cisapride for gastro-oesophageal reflux and peptic oesophagitis. Arch Dis Child 1987; 62:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/40\">",
"      Augood C, MacLennan S, Gilbert R, Logan S. Cisapride treatment for gastro-oesophageal reflux in children. Cochrane Database Syst Rev 2003; :CD002300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/41\">",
"      Leung C, Lai W. Use of metoclopramide for the treatment of gastroesophageal reflux in infants and children. Curr Ther Res 1984; 36:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/42\">",
"      Machida HM, Forbes DA, Gall DG, Scott RB. Metoclopramide in gastroesophageal reflux of infancy. J Pediatr 1988; 112:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/43\">",
"      Bellissant E, Duhamel JF, Guillot M, et al. The triangular test to assess the efficacy of metoclopramide in gastroesophageal reflux. Clin Pharmacol Ther 1997; 61:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/44\">",
"      De Loore I, Van Ravensteyn H, Ameryckx L. Domperidone drops in the symptomatic treatment of chronic paediatric vomiting and regurgitation. A comparison with metoclopramide. Postgrad Med J 1979; 55 Suppl 1:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/45\">",
"      Tolia V, Calhoun J, Kuhns L, Kauffman RE. Randomized, prospective double-blind trial of metoclopramide and placebo for gastroesophageal reflux in infants. J Pediatr 1989; 115:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/46\">",
"      Craig WR, Hanlon-Dearman A, Sinclair C, et al. Metoclopramide, thickened feedings, and positioning for gastro-oesophageal reflux in children under two years. Cochrane Database Syst Rev 2004; :CD003502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/47\">",
"      Hibbs AM, Lorch SA. Metoclopramide for the treatment of gastroesophageal reflux disease in infants: a systematic review. Pediatrics 2006; 118:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/48\">",
"      Ciccaglione AF, Marzio L. Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut 2003; 52:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/49\">",
"      Omari TI, Benninga MA, Sansom L, et al. Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. J Pediatr 2006; 149:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/50\">",
"      Kawai M, Kawahara H, Hirayama S, et al. Effect of baclofen on emesis and 24-hour esophageal pH in neurologically impaired children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2004; 38:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/51\">",
"      Djeddi D, Kongolo G, Lefaix C, et al. Effect of domperidone on QT interval in neonates. J Pediatr 2008; 153:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/52\">",
"      Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol 2005; 26:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/53\">",
"      Van Eygen M, Dhondt F, Heck E, et al. A double-blind comparison of domperidone and metoclopramide suppositories in the treatment of nausea and vomiting in children. Postgrad Med J 1979; 55 Suppl 1:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/54\">",
"      Bines JE, Quinlan JE, Treves S, et al. Efficacy of domperidone in infants and children with gastroesophageal reflux. J Pediatr Gastroenterol Nutr 1992; 14:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/55\">",
"      Carroccio A, Iacono G, Montalto G, et al. Domperidone plus magnesium hydroxide and aluminum hydroxide: a valid therapy in children with gastroesophageal reflux. A double-blind randomized study versus placebo. Scand J Gastroenterol 1994; 29:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/56\">",
"      Pritchard DS, Baber N, Stephenson T. Should domperidone be used for the treatment of gastro-oesophageal reflux in children? Systematic review of randomized controlled trials in children aged 1 month to 11 years old. Br J Clin Pharmacol 2005; 59:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/57\">",
"      Euler AR. Use of bethanechol for the treatment of gastroesophageal reflux. J Pediatr 1980; 96:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/58\">",
"      Levi P, Marmo F, Saluzzo C, et al. Bethanechol versus antiacids in the treatment of gastroesophageal reflux. Helv Paediatr Acta 1985; 40:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/59\">",
"      Poynard T, Vernisse B, Agostini H. Randomized, multicentre comparison of sodium alginate and cisapride in the symptomatic treatment of uncomplicated gastro-oesophageal reflux. Aliment Pharmacol Ther 1998; 12:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/60\">",
"      Greally P, Hampton FJ, MacFadyen UM, Simpson H. Gaviscon and Carobel compared with cisapride in gastro-oesophageal reflux. Arch Dis Child 1992; 67:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/61\">",
"      Buts JP, Barudi C, Otte JB. Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children. Eur J Pediatr 1987; 146:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/62\">",
"      Forbes D, Hodgson M, Hill R. The effects of gaviscon and metoclopramide in gastroesophageal reflux in children. J Pediatr Gastroenterol Nutr 1986; 5:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/63\">",
"      Simon B, Ravelli GP, Goffin H. Sucralfate gel versus placebo in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1996; 10:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/64\">",
"      Arg&uuml;elles-Martin F, Gonzalez-Fernandez F, Gentles MG. Sucralfate versus cimetidine in the treatment of reflux esophagitis in children. Am J Med 1989; 86:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/65\">",
"      Rothenberg SS. Experience with 220 consecutive laparoscopic Nissen fundoplications in infants and children. J Pediatr Surg 1998; 33:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/66\">",
"      Dalla Vecchia LK, Grosfeld JL, West KW, et al. Reoperation after Nissen fundoplication in children with gastroesophageal reflux: experience with 130 patients. Ann Surg 1997; 226:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/67\">",
"      Bensoussan AL, Yazbeck S, Carceller-Blanchard A. Results and complications of Toupet partial posterior wrap: 10 years' experience. J Pediatr Surg 1994; 29:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/68\">",
"      Fonkalsrud EW, Ashcraft KW, Coran AG, et al. Surgical treatment of gastroesophageal reflux in children: a combined hospital study of 7467 patients. Pediatrics 1998; 101:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/69\">",
"      Fonkalsrud EW, Bustorff-Silva J, Perez CA, et al. Antireflux surgery in children under 3 months of age. J Pediatr Surg 1999; 34:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/70\">",
"      Weber TR. Toup&eacute;t fundoplication for gastroesophageal reflux in childhood. Arch Surg 1999; 134:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/71\">",
"      Gilger MA, Yeh C, Chiang J, et al. Outcomes of surgical fundoplication in children. Clin Gastroenterol Hepatol 2004; 2:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/72\">",
"      Cheung KM, Tse HW, Tse PW, Chan KH. Nissen fundoplication and gastrostomy in severely neurologically impaired children with gastroesophageal reflux. Hong Kong Med J 2006; 12:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/73\">",
"      Tovar JA, Olivares P, Diaz M, et al. Functional results of laparoscopic fundoplication in children. J Pediatr Gastroenterol Nutr 1998; 26:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/74\">",
"      Diaz DM, Gibbons TE, Heiss K, et al. Antireflux surgery outcomes in pediatric gastroesophageal reflux disease. Am J Gastroenterol 2005; 100:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/75\">",
"      Kane TD, Brown MF, Chen MK, Members of the APSA New Technology Committee. Position paper on laparoscopic antireflux operations in infants and children for gastroesophageal reflux disease. American Pediatric Surgery Association. J Pediatr Surg 2009; 44:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/76\">",
"      Hassall E. Outcomes of fundoplication: causes for concern, newer options. Arch Dis Child 2005; 90:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/77\">",
"      Taylor LA, Weiner T, Lacey SR, Azizkhan RG. Chronic lung disease is the leading risk factor correlating with the failure (wrap disruption) of antireflux procedures in children. J Pediatr Surg 1994; 29:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/78\">",
"      Boesch RP, Acton JD. Outcomes of fundoplication in children with cystic fibrosis. J Pediatr Surg 2007; 42:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/79\">",
"      Tovar JA, Luis AL, Encinas JL, et al. Pediatric surgeons and gastroesophageal reflux. J Pediatr Surg 2007; 42:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/80\">",
"      Kristensen C, Avitsland T, Emblem R, et al. Satisfactory long-term results after Nissen fundoplication. Acta Paediatr 2007; 96:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/81\">",
"      O'Loughlin EV, Somerville H, Shun A, et al. Antireflux surgery in children with neurological impairment: caregiver perceptions and complications. J Pediatr Gastroenterol Nutr 2013; 56:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/82\">",
"      Antao B, Ooi K, Ade-Ajayi N, et al. Effectiveness of alimemazine in controlling retching after Nissen fundoplication. J Pediatr Surg 2005; 40:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/83\">",
"      Tovar JA, Angulo JA, Gorostiaga L, Arana J. Surgery for gastroesophageal reflux in children with normal pH studies. J Pediatr Surg 1991; 26:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/84\">",
"      Gold BD. Asthma and gastroesophageal reflux disease in children: exploring the relationship. J Pediatr 2005; 146:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/85\">",
"      Gibson PG, Henry RL, Coughlan JL. Gastro-oesophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev 2003; :CD001496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/86\">",
"      Mattioli G, Sacco O, Repetto P, et al. Necessity for surgery in children with gastrooesophageal reflux and supraoesophageal symptoms. Eur J Pediatr Surg 2004; 14:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/87\">",
"      Bowrey DJ, Peters JH, DeMeester TR. Gastroesophageal reflux disease in asthma: effects of medical and surgical antireflux therapy on asthma control. Ann Surg 2000; 231:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/33/19994/abstract/88\">",
"      Rothenberg S, Cowles R. The effects of laparoscopic Nissen fundoplication on patients with severe gastroesophageal reflux disease and steroid-dependent asthma. J Pediatr Surg 2012; 47:1101.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5900 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-5969107613-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_33_19994=[""].join("\n");
var outline_f19_33_19994=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LIFESTYLE CHANGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Proton pump inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Histamine type 2 receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antacids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Surface agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pre-surgical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EXTRAESOPHAGEAL MANIFESTATIONS OF GERD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Asthma with GER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Recurrent pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Treatment options",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Heartburn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Esophagitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Dysphagia or odynophagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5900\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5900|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/62/995\" title=\"figure 1\">",
"      Anti GERD operations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5900|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/0/12302\" title=\"table 1\">",
"      Drugs for GERD in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=related_link\">",
"      Clinical manifestations and diagnosis of acute interstitial nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16745?source=related_link\">",
"      Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39816?source=related_link\">",
"      Gastroesophageal reflux and asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30441?source=related_link\">",
"      Gastroesophageal reflux in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23657?source=related_link\">",
"      Gastroesophageal reflux in premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25034?source=related_link\">",
"      Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/50/32547?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in children and adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/11/40114?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in children and adolescents (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16643?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42905?source=related_link\">",
"      Surgical management of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/41/1689?source=related_link\">",
"      Wheezing illnesses other than asthma in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_33_19995="Protocol for cervical length screening";
var content_f19_33_19995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Approach to transvaginal ultrasound (TVU) measurement of cervical length for screening singleton gestations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Past pregnancy history",
"       </td>",
"       <td class=\"subtitle1\">",
"        TVU cervical length screening",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prior preterm birth 14 to 27 weeks",
"       </td>",
"       <td>",
"        Start at 14 weeks and end at 24 weeks",
"       </td>",
"       <td>",
"        Every 2 weeks as long as cervix is at least 30 mm*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prior preterm birth 28 to 36 weeks",
"       </td>",
"       <td>",
"        Start at 16 weeks and end at 24 weeks",
"       </td>",
"       <td>",
"        Every 2 weeks as long as cervix is at least 30 mm*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No prior preterm birth",
"       </td>",
"       <td>",
"        One exam between 18 and 24 weeks",
"       </td>",
"       <td>",
"        Once",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Increase frequency to weekly in women with TVU cervical length of 25 to 29 mm. If &lt;25 mm before 24 weeks, consider cerclage.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     If &le;20 mm before 25 weeks, consider progesterone supplementation.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_33_19995=[""].join("\n");
var outline_f19_33_19995=null;
var title_f19_33_19996="Dx criteria somatization";
var content_f19_33_19996=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F73363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F73363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DSM-IV-TR diagnostic criteria for somatization disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         A.",
"        </strong>",
"        A history of many physical complaints that begin before age 30, occur over a period of several years, and lead to seeking treatment or to significant impairment in occupational, social, or other important areas of functioning.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         B.",
"        </strong>",
"        Each of the following criteria must have been met, with individual symptoms occurring at any time during the course of the disturbance:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Four pain symptoms: a history of pain related to at least four different sites or functions (eg, head, abdomen, back, joints, extremities, chest, rectum, during menstruation, during sexual intercourse, or during urination)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Two gastrointestinal symptoms: a history of at least two gastrointestinal symptoms other than pain (eg, nausea, bloating, vomiting other than during pregnancy, diarrhea, or intolerance of several different foods)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. One sexual symptom: a history of at least one sexual or reproductive symptom other than pain (eg, sexual indifference, erectile or ejaculatory dysfunction, irregular menses, excessive menstrual bleeding, vomiting throughout pregnancy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. One pseudoneurological symptom: a history of at least one symptom or deficit suggesting a neurological condition not limited to pain (conversion symptoms such as impaired coordination or balance, paralysis or localized weakness, difficulty swallowing or lump in throat, aphonia, urinary retention, hallucinations, loss of touch or pain sensation, double vision, blindness, deafness, seizures; dissociative symptoms such as amnesia; or loss of consciousness other than fainting)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         C.",
"        </strong>",
"        Either (1) or (2):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. After appropriate investigation, each of the symptoms in criterion B cannot be fully explained by a known general medical condition or the direct effects of a substance (eg, a drug of abuse, a medication)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. When there is a related general medical condition, the physical complaints or resulting social or occupational impairment are in excess of what would be expected from the history, physical examination, or laboratory findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         D.",
"        </strong>",
"        The symptoms are not intentionally produced or feigned (as in Factitious Disorder or Malingering).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Text Revision, Fourth Edition. Copyright &copy; 2000 American Psychiatric Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_33_19996=[""].join("\n");
var outline_f19_33_19996=null;
var title_f19_33_19997="Initial functional assessment hosp older adults";
var content_f19_33_19997=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Initial functional assessment for hospitalized older adults*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Self-care (physical or cognitive function)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <ul>",
"         <li>",
"          IADLs",
"          <sup>",
"           &loz;",
"          </sup>",
"          <br/>",
"          - Are you able to pay your own bills, or do you need help with your checkbook?",
"          <br/>",
"          - Do you do your own cooking?",
"          <br/>",
"          - How do you get to your doctor appointments?",
"         </li>",
"         <li>",
"          Do you sometimes find yourself confused? (Mini-Cog",
"          <sup>",
"           &sect;",
"          </sup>",
"          <sup>",
"           [1]",
"          </sup>",
"          )",
"         </li>",
"         <li>",
"          Can you climb a flight of stairs? If not, what limits you? (eg, pain, dyspnea, strength, balance)",
"         </li>",
"         <li>",
"          Do you require assistance with bathing? (ADLs",
"          <sup>",
"           &yen;",
"          </sup>",
"          )",
"         </li>",
"         <li>",
"          When was the last time you fell? What happened?",
"         </li>",
"         <li>",
"          Do you have difficulty with balance or walking?",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Advance directives",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <ul>",
"         <li>",
"          Do you have an advance directive?",
"         </li>",
"         <li>",
"          Who would you like to help you make medical decisions, or make them in your place in the event you are unable to participate in the discussion?",
"         </li>",
"         <li>",
"          Rank the following (in order of preference) of how you would like us to focus your care",
"          <sup>",
"           [2]",
"          </sup>",
"          :",
"          <br/>",
"          1) Life prolongation",
"          <br/>",
"          2) Maintaining function",
"          <br/>",
"          3) Comfort",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Living situation and social support",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <ul>",
"         <li>",
"          Who do you turn to when you need help?",
"         </li>",
"         <li>",
"          Who do you live with?",
"         </li>",
"         <li>",
"          What kind of help do you have at home?",
"         </li>",
"         <li>",
"          Where you live, do you have:",
"          <br/>",
"          - Meals prepared for you",
"          <br/>",
"          - Help taking your pills, checking your blood sugar, etc",
"          <br/>",
"          - Do you need to climb stairs to get to your apartment/home/bedroom?",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        General screening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nutrition",
"       </td>",
"       <td>",
"        Have you lost any weight in the last year?",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Visual impairment",
"       </td>",
"       <td>",
"        Do you have difficulty driving, watching TV, or reading because of your eyesight?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hearing",
"       </td>",
"       <td>",
"        Do you have difficulty hearing or understanding what a person says talking in a normal voice?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urinary incontinence",
"       </td>",
"       <td>",
"        Do you sometimes lose control of your urine and, if so, is that bothersome to you?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IADLs: instrumental activities of daily living; ADL: activities of daily living.",
"     <br>",
"      * See the US Department of State's \"Caring for Elderly Parents\" website at:",
"      <a href=\"file://www.state.gov/m/dghr/flo/c23141.htm\" target=\"_blank\">",
"       file://www.state.gov/m/dghr/flo/c23141.htm",
"      </a>",
"      .",
"      <br>",
"       &Delta; (See \"Evaluation of cognitive impairment and dementia,\" section on \"Mini-Cog\" and \"Falls in older persons: Risk factors and patient evaluation,\" section on \"Falls risk assessment.\")",
"       <br>",
"        &loz; IADLs: Using the telephone, shopping, preparing meals, housekeeping, doing laundry, using public transportation or driving, taking medication, handling finances.",
"        <br>",
"         &sect; Mini-Cog: Three item recall and clock drawing test.",
"         <br>",
"          &yen; ADLs: Bathing, dressing, toileting, transferring, maintaining continence, feeding.",
"          <br>",
"            (See \"Legal aspects of end of life care,\" section on \"Advance directives\" and \"Comprehensive geriatric assessment\".)",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Borson S, Scanlan J, Brush M, et al. The Mini-Cog: A cognitive 'vital signs' measure for dementia screening in multi-lingual elderly. Int J Geriatr Psychiatry 2000; 15:1021.",
"       </li>",
"       <li>",
"        Gillick MR. Choosing appropriate medical care for the elderly. J Am Med Dir Assoc 2001; 2:305.",
"       </li>",
"       <li>",
"        Wallace JI, Schwartz RS, LaCroix AZ, et al. &ldquo;Involuntary weight loss in older outpatients. J Am Geriatr Soc 1995; 43:329.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_33_19997=[""].join("\n");
var outline_f19_33_19997=null;
var title_f19_33_19998="International homicide rates";
var content_f19_33_19998=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    International variation in homicide rates",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 417px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    International homicide rates per 100,000 people 2008 to 2010.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Global Study on Homicide 2011. United Nations Office on Drugs and Crime 2012. Full report available at:",
"     <a href=\"file://www.unodc.org/unodc/en/data-and-analysis/statistics/crime/global-study-on-homicide-2011.html\" target=\"_blank\">",
"      file://www.unodc.org/unodc/en/data-and-analysis/statistics/crime/global-study-on-homicide-2011.html",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_33_19998=[""].join("\n");
var outline_f19_33_19998=null;
var title_f19_33_19999="Colon diverticulae scleroderma";
var content_f19_33_19999=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F81427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F81427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Colonic diverticulae in scleroderma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Barium enema in a patient with scleroderma shows wide- mouthed colonic diverticulae (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD, FRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_33_19999=[""].join("\n");
var outline_f19_33_19999=null;
